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ABSTRACT 
_____________________________________________________________________________________ 
 
Background 
The  combined  influence of processes of care, lifestyle advice and drug treatment on glycaemic control 
in Type 2 diabetes in primary care settings  is not well documented. 
Aim 
To describe the provision of lifestyle advice, selected processes of care and drug treatment to, and 
assess the influence of these factors on glycaemic control in, a sample of  adults with type 2 diabetes 
mellitus attending the Johan Heyns Community Health Centre  in Sedibeng District, Gauteng. 
Methods 
A cross-sectional design was used. Participants consisted of 200, consecutively chosen, adult volunteers 
with type 2 diabetes. Information on demographics, reported receipt of lifestyle  advice  and 
anthropomorphic measurements was collected through questionnaire-based interviews. This was 
followed by a record review of all participants’ clinic files for information on current drug management, 
co-morbid medical conditions and documentation of processes of care, in the preceding 12 months, in 
respect of HbA1c, blood pressure (BP), weight, waist circumference (WC) and body mass index (BMI) 
monitoring.  HbA1c values were used to ascertain glycaemic control.  Performance of processes of care 
was assessed in accordance with  Society for Endocrinology, Metabolism and Diabetes of South Africa 
(SEMDSA) guidelines. Parsimonious models for glycaemic control were constructed through multivariate 
logistic regression. 
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Results 
Mean age of  the  sample  was 58 years with 58% in the 50-64 year age group. Blacks (88%) and females 
(63%) were in the majority. 
Over two-thirds had diabetes for  under 10 years and 98% had at least one co-morbid condition, mainly 
hypertension (92%). Obesity was  noted  in 65%, while 95% of females and 83% of males had a WC that 
conferred substantial cardio-metabolic risk. 
Receipt of advice on any of diet, exercise or weight control from a health professional in the preceding 
12 months was reported by 79%, with 67% reporting receipt of advice on all three. 
Under  2% of patient records met the SEMDSA standard for processes of care for HbA1c, weight, WC and 
BMI monitoring, while 93% achieved the standard for BP monitoring. 
Exclusive oral treatment was prescribed in 62%, and the majority of these were on combined metformin 
and sulphonylurea;  5% were on insulin monotherapy. 
Optimal glycaemic control (HbA1c < 7%) was noted in only 25% of the sample. 
On multivariate analyses, the presence of CCF conferred higher odds of controlled glycaemia (OR = 3.17, 
P = 0.035). Compared with insulin monotherapy,  treatment with either combined metformin and insulin 
(OR = 0.216, P = 0.02), or with the combination of all 3 drug classes ( metformin, sulphonylurea and 
insulin) (OR = 0.185, P = 0.027), conferred  lower odds of glycaemic control.  
Conclusions 
This study highlights substantial shortcomings in the compliance with key processes of care and the 
achievement of optimal glycaemic control for type 2 diabetes mellitus in the current research setting.  
An inverse  association was noted  between glycaemic control and the use of combined oral and insulin 
drug therapy. Measured processes of care and reported receipt of lifestyle advice showed no association 
with glycaemic control. CCF co-morbidity conferred improved odds of controlled glycaemia. 
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CHAPTER 1 
INTRODUCTION 
_____________________________________________________________________________________ 
1.1 Background 
Type 2 diabetes is a devastating condition responsible for high levels of morbidity and mortality.  Four 
million diabetes related deaths occur each year worldwide and an estimated 5% of all deaths in Sub-
Saharan Africa is  attributed to the disease.
1
  According to the International Diabetes Federation (IDF), 
deaths attributable to diabetes in South Africa in 2010 amounted to 45 957
2
, a more than 2-fold 
increase on the figure estimated for 2000.
3
 
The excess morbidity and mortality seen in individuals with Type 2 diabetes occur mainly as a result of 
macro-and micro-vascular pathology resulting in cardiovascular, neurological, ophthalmic and renal 
complications.
4,5
 
An impressive body of evidence exists from studies such as the ground-breaking United Kingdom 
Prospective Diabetes Study (UKPDS)
6,7,8
  demonstrating  the link between glycaemic control and diabetic 
complications, especially those attributable to micro-vascular pathology.  Even prior to the UKPDS, there 
existed strong evidence to suggest that improved glycaemic control decreased the risk of retinopathy, 
nephropathy and neuropathy in Type 2 diabetics.
9
  
A cornerstone in the management of type 2 diabetes is the clinical management of glycaemia and 
protocols for doing this have been articulated in evidence-based guidelines both In South Africa and 
internationally.
10,11
   
 2 
 
These protocols include both pharmacological and non-pharmacological modalities for glycaemic control 
together with a clearly defined set of processes of care; in addition, they emphasize the responsibility of 
health care professionals in the provision of advice on, inter-alia, lifestyle modification.  
A number of South African studies demonstrate a pattern of inadequate compliance with these 
components of clinical management, as well as unsatisfactory levels of glycaemic control.
12-17
  The 
majority of these studies describe the levels of glycaemic control and/or compliance with processes of 
care
12,13, 15-17
; one study documented receipt of  lifestyle advice
14 
while two other studies looked at the 
association of some processes of care and glycaemic control
13,15
, one of which was at a tertiary level 
facility.
13
  Of all the available studies reviewed at the time of the present study, none sought to 
comprehensively look at the influence of processes of care, lifestyle advice and drug treatment on 
glycaemic control. 
1.2 Motivation and Rationale 
In Sedibeng District, data on glycaemic control, drug treatment and process of care performance and 
dissemination of lifestyle advice by clinicians, are not integral components of the district health 
information system (DHIS).  Consequently, this information is not captured and unknown.  A previous 
audit focusing on processes of care amongst a sample of adult type 2 diabetics at the Johan Heyns 
Community Health Centre in Sedibeng District found that performance of some process of care 
elements varied between 0 and 49%, while controlled glycaemia was noted to be achieved in no more 
than 30%.
18
 
 While it has been documented that overall levels of glycaemic control in various primary care settings 
are inadequate, the influence of receipt of lifestyle advice by patients, clinicians’ practice regarding 
processes of care, and drug treatment   on such control, has not been adequately studied. 
 3 
 
The current study therefore seeks to describe the provision process of care, drug treatment and  lifestyle 
advice by health care workers to adults with Type 2 diabetes in a CHC in Sedibeng District. It 
furthermore assesses the influence of these factors on glycaemic control.  It is envisaged that  the 
identification of one or more of these, potentially modifiable  components of clinical care,  could  inform 
interventions aimed at  improving  the quality of diabetic care and  glycaemic control in primary care 
facilities  within the district and in similar settings elsewhere. 
 
1.3 Aim and Objectives 
1.3.1 Aim 
This study aims to describe the provision of lifestyle advice, selected processes of care and drug 
treatment to, and assess the influence of these factors on glycaemic control in, adults with type 2 
diabetes mellitus attending the Johan Heyns Community Health Centre in Sedibeng District, Gauteng.  
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1.3.2 Objectives 
• To estimate the current levels of glycaemic control in the study population. 
• To estimate the proportion of patients that had each of the following processes of care 
performed with the indicated frequency in the preceding 12  months in accordance with  Society 
for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) recommendations10 : 
o BP  measurement at every visit 
o BMI measured  once in 12 months 
o Weight and waist circumference measured at every visit 
o HbA1c  measured at least twice in 12 months 
• To  estimate the proportion of patients that reported  receipt of information from a health 
worker at the facility in the last 12 months on the following lifestyle measures: 
o The importance of weight control 
o Exercise 
o Diet 
• To describe the current diabetic drug regimens as prescribed in clinic records. 
• To  uncover possible associations between current glycaemic control and the following factors: 
o Reported receipt of advice on: weight control, exercise and diet 
o Processes of care indicators for HbA1c, blood pressure, weight, BMI and waist 
circumference monitoring 
o Current diabetic  medication  
o Other demographic and clinical factors 
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CHAPTER 2 
LITERATURE REVIEW 
_____________________________________________________________________________________ 
2.1   Literature search and structure of the chapter 
 Articles used for this literature review were identified primarily using PubMed and Medline, and were 
confined to studies on human subjects published in English.  Initial searches were conducted on medical 
subject headings using the following terms either alone or in combination: “type 2 diabetes” , 
“glycaemic control” ,  “exercise”,  “diet” , “weight control”, “lifestyle advice” , “processes of care”  and  
“treatment”.  Relevance of retrieved studies was assessed based both on study titles, as well as content 
and, cross referencing from these, identified further articles for consideration. References have been 
mainly limited to key articles published within the last 20 years; however, where deemed appropriate, 
older articles were also considered for inclusion. 
This chapter on the literature review commences with a brief consideration of the patho-physiology and 
prevalence of type 2 diabetes and then proceeds to consider the key topics contained in the aim of the 
present research.  
2.2  Pathophysiology of type 2 diabetes mellitus 
Diabetes Mellitus is a group of metabolic diseases whose main characteristic is chronic hyperglycaemia 
arising from either defective insulin secretion from the pancreas, defective insulin action on target 
organs, or both.
19,20
  The simplest way to classify diabetes is to look at whether the condition is primary 
or secondary.
5
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These 2 basic categories however, subsume a number of additional sub-categories that are accounted 
for in the following, much broader, clinical classification by the American Diabetic Association (ADA)
19,11 
: 
• Type 1 diabetes mellitus: results from β-cell destruction leading to an absolute insulin deficiency 
• Type 2 diabetes mellitus: results from a variable combination of insulin secretion defects and 
insulin resistance ranging from a predominance of insulin resistance with relative insulin 
deficiency, to a predominantly insulin secretory defect with insulin resistance. 
• Specific types of diabetes due to other causes: 
o Genetic defects in β-cell function 
o Genetic defects in insulin action 
o Diseases of the exocrine pancreas 
o Drug or chemically induced 
• Gestational diabetes (GDM):  diabetes diagnosed during pregnancy that is clearly not overt 
diabetes.  
The patho-physiologic hallmark of Type 2 diabetes is insulin resistance with relative insulin 
insufficiency.20  Initially, increase in pancreatic insulin secretion compensates for insulin resistance. 
When β-cell depletion occurs, the pancreas is no longer able to maintain compensatory 
hyperinsulinaemia and there is dysregulation of glucose homeostasis: peripheral uptake is 
compromised, counter-regulatory feedback on glucagon is diminished and glucose intolerance and 
hyperglycaemia supervene.
5,19,20 
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Type 2 diabetes is a multi-factorial disease with both genetic and environmental risk factors. There is an 
increased risk associated with
5,20 
: 
• Inheritance 
• Obesity 
• Increasing age 
• Lack of physical activity 
Other determinants of the disease include20,21  : 
• Females with prior GDM 
• Race/ethnicity 
 
2.3 Epidemiology 
Worldwide, this disease has reached epidemic proportions.  Estimates from 2007 suggest that it had 
already affected 171 million people worldwide, with India, a hotbed of this disease, accounting for 
almost 32 million cases.
4
 More recent estimates place worldwide prevalence even higher
22 
: amongst 
adults in the 20-79 year age group, prevalence was estimated to be 6.4% or approximately 285 million 
people.  This figure is expected to escalate to 7.7% or 439 million adults worldwide by 2030.
22
   Between 
2010 and 2030, developed countries are expected to experience a 20% increase in prevalence; the 
expected increase in the developing world is predicted to be over 3-fold higher at 69%.
22
  In 3 of the 6 
developing regions, namely the Middle East and North Africa, South Asia, and Sub-Saharan Africa, the 
prevalence is expected to double from 2000 to 2030. In Sub-Saharan Africa specifically, the prevalence 
increase is projected to be 97%.
23
 In Africa as a whole, the prevalence of diabetes is expected to increase 
from just below 4% in 2010 to almost 5% in 2030.
1
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Prevalence figures for South Africa show a similar trend.  Data published by the International Diabetes 
Federation (IDF) placed the prevalence of diabetes amongst adults aged 20-79 in 2003 at 3.4%. 
24
   This is 
expected to rise to 5.6% by 2030.
2
  
There are very few recent province specific prevalence figures for South Africa but past studies from the 
period 1993-1999 reveal a varied picture: most studies were conducted in the Cape Town and Durban 
urban areas and most were race specific with only 2 of the 7 studies, conducted in Cape Town, looking 
at a mixed race study population.
25
   In the latter, prevalence varied from 10.8% to 28.7%.  A more 
recent study in rural southern Free State estimated the prevalence of the disease there to be 7.6%.
26
 
 
2.4  The Importance of glycaemic control 
Type 2 diabetes is not a benign disease; it is a devastating condition with high levels of morbidity and 
mortality. Globally, 4 million diabetes related deaths occur each year
4 
;  this translates to approximately 
11 000 deaths each day.  In Africa, diabetes related mortality as a proportion of all deaths was estimated 
to be 6% in 2010 with 1 in 20 of all such deaths occurring in Sub-Saharan Africa.
1
   A study in 2007 by 
Bradshaw et al.,  to estimate the burden of diabetes related disease in South Africa  in 2000, found that 
14% of all  ischaemic heart disease (IHD), 10% of all strokes and 12% of all renal disease amongst adults 
aged 30 years or older, could be attributable to the disease; in addition, 258 025 disability-adjusted life 
years (DALY’s) and 22 415 deaths  were attributed to the disease.3 According to the IDF, deaths 
attributable to diabetes in South Africa in 2010 amounted to 45 9572 ;  this represents a more than  2-
fold increase on  the figure estimated for 2000 by Bradshaw et al.3  
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The high levels of morbidity and mortality seen with the disease are largely due to micro- and macro-
vascular complications.
4,17
  A critical factor in the prevention of micro- and macrovascular complications 
is  glycaemic control, a  fact  demonstrated by a number of extensive trials in the past decade and a   
half. 
6-8,27,28
 
The earliest convincing evidence for the link between glycaemic control and microvascular  
complications  was provided by research which examined the effects of intensive glycaemic control in 
insulin dependent diabetics.
27,28
   The first of these studies, the Stockholm Diabetes Intervention Study 
(SDIS), was a small randomized control trial that showed a significantly reduced occurrence of 
nephropathy, neuropathy and proliferative retinopathy requiring photocoagulation associated with 
better glycaemic control.
27
   These results were observed despite the fact that the mean HbA1c achieved 
in the intervention arm was 7.2%,  which is slightly higher than what is currently accepted as normal. 
More evidence for the effect of intensive glycaemic control on long term microvascular complications   
in IDDM was demonstrated by The Diabetic Control and Complications Trial (DCCT).
28
  In this   large, 
multicentre, randomized clinical trial, a significant reduction in risk, for both the development and 
progression of retinopathy was demonstrated in the intervention arm: risk for development of 
retinopathy was reduced by 76% and progression of retinopathy was reduced by 54%. In addition, there 
were also significant reductions in the occurrence of microalbuminuria, albuminuria and clinical 
neuropathy. 
While the DCCT provided the first clear evidence of an association between glycaemic control and 
complications, this association in Type 2 diabetics remained untested in any large scale trial.  The 
landmark trial that firmly established the importance of glycaemic control in Type 2 diabetics was the 
United Kingdom Prospective Diabetes Study (UKPDS).
6-8
  In this large, multicentre, prospective  
randomized  trial conducted at 23 clinical centres, 5102 participants, aged between 25-65 years, with 
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newly diagnosed Type 2 diabetes  were enrolled between 1977 and 1991.
8
  The aim  was to compare the 
effects of intensive blood glucose control with that of conventional treatment with diet alone, on the 
risk of developing microvascular and macrovascular complications in newly diagnosed Type 2 diabetics.  
Patients were randomized to receive either conventional therapy consisting of diet alone or intensive 
therapy consisting of diet and medication. The intervention cohort was further categorized into 2 
groups: 
• UKPDS 33:patients who received sulphonylureas or  insulin or both
6
 
• UKPDS 34: patients whose bodyweight was greater than 120% of ideal received metformin7 
Median follow-up times were 10.0 and 10.7 years for the 2 groups respectively. The researchers used 3 
aggregate endpoints to assess the difference in outcomes in the study arms
6,7
 : 
• Any diabetes related endpoint 
• Diabetes related death 
• All-cause mortality 
 A significant 12% lower risk (P=0.029) for any diabetes related endpoint, was achieved in the 
sulphonylurea/insulin arm compared to the conventional treatment arm.
6
  While risk reductions of 10% 
and 6% were noted for any diabetes related death and all-cause mortality respectively, the associations 
were not statistically significant. The researchers also noted that the risk reduction for any diabetes 
related endpoint was achieved largely due to a 25% risk reduction in microvascular complications.  An 
important negative finding was the absence of significant risk reduction for macrovascular 
complications. The metformin arm showed even more impressive risk reductions compared to the 
conventional treatment arm: 32% lower risk (P=0.002) for any diabetes related endpoint, 42% lower risk 
(P=0.017) for any diabetes related death and 36% lower risk (P=0.011) for all-cause mortality.
7
 
Furthermore, unlike the sulphonylurea/insulin arm, which failed to demonstrate any risk reduction for 
 11 
 
myocardial infarction, a 39% risk reduction (P=0.01) for the same endpoint was observed in the 
metformin arm.
6-8 
 Prior to the UKPDS, results from a number of studies hinted at  the beneficial effects 
of improved glycaemic control on complications in type 2 diabetes
9
 ;   findings  from the UKPDS provided 
the first clear evidence for this association. 
 
2.5  Prevalence of glycaemic  control 
Globally, glycaemic control amongst Type 2 diabetics is unsatisfactory.    An analysis of National Health 
and Nutritional Examination Survey (NHANES) data  by Saadine et al, showed that 47% of people with 
Type 2 diabetes had HbA1c < 7% and found a non significant improvement in the proportion of patients 
with poor (HbA1c > 9.0g/dl) glycaemic control between 1999 and 2002.  More importantly, the same 
study noted that: “1 in 5 patients still had poor glycaemic control.” 29   A more comprehensive picture of 
glycaemic control trends using NHANES data for the period 1999-2004 was provided by Hoerger et. al.30 
Their analysis showed that the proportion of individuals with HbA1c < 7% increased from 40% for the 
period 1999-2000, to 57% for the period 2003-2004.  However, mean HbA1c, which was estimated to be 
7.82% for the period 1999-2000, showed no statistically significant decrease. 
 As part of a diabetes quality improvement program in community health centres in the United States, 
the Community Health Centre Network measured the prevalence of  diabetic control and found similar 
results: 27%  had poor  glycaemic control.31  The Delhi Diabetes Community Survey,  a cross-sectional 
study conducted by Nagpal and and Bhartia , which investigated the quality of diabetic care amongst a 
middle and  high income population in Delhi,  reported poor glycaemic control( HbA1c > 8) in  42% of 
diabetics surveyed.32 
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 In South Africa, there is a dearth of data on glycaemic control amongst diabetics. Available information 
points to inadequate levels of control. In a survey of hypertensive and diabetic patients conducted at 18 
community health centres in the Cape Peninsula, Steyn et.al., found that 76% had an HbA1c greater 
than or equal to 1% of the upper limit of normal (they used 5.9% as the upper limit of normal), while 
57.9% had a random blood glucose greater than 11.1 mmol/l.
15
  As part of a quality improvement 
project to address shortcomings in diabetic  care at a rural hospital in KwaZulu-Natal,  a post 
intervention audit showed that only 10% of patients with Type 2 diabetes had an HbA1c of less than 7; 
furthermore, in 57%, the HbA1c was greater than or equal to 10.
12
   Another study also in rural KwaZulu-
Natal  amongst patients attending both primary and secondary care facilities, found  a mean HbA1c of 
11.2%  in  Type 2 diabetics.
16
 
 
2.6  The processes of care in type 2 diabetes 
A key responsibility of the physician entrusted with the care of diabetics is attention to processes of care 
issues. Processes of care refer to those activities that a physician undertakes such as regular HbA1c 
checks, urine checks, eye and feet examinations and others that define quality of care in diabetes.
33,34
  
As such, adherence to process of care measures is a necessary condition for the achievement of desired 
outcomes, which are: good glycaemic control, and, the detection and prevention of complications.  A 
process of care has 2 components: the actual process or activity itself, and the frequency with which it 
should be carried out.
10
 Recommendations for processes of care vary and are contained in various 
national and international guidelines based on current evidence.
10,11
  They include a wide range of 
activities, from routine processes such as blood glucose, blood pressure and body weight checks, to 
more specialized activities such as retinopathy and nephropathy screening.  Also included are adjunctive 
processes for the prevention of cardio- and renovascular complications using anti-platelet, lipid lowering 
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and ACE inhibitor medication.  A useful categorization of the various processes is provided by Bailie et. 
al.
35
  This distinguishes between basic and specialized processes, investigations and counseling/inquiry 
processes.   Basic processes  include monitoring the following: 
• Weight 
• Blood pressure 
• Waist circumference 
• Body Mass Index ( BMI) 
• Blood glucose 
• Urine dipstix 
 
Specialized processes include performing the following: 
• Peripheral pulses check 
• Visual acuity check 
• Optic fundi examination 
• Feet examination 
• Opthalmologist referral 
• Vaccinations 
 
Investigations: 
• Tests for renal function 
• HbA1c 
• Lipids 
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Counseling/inquiry processes: 
• Diet 
• Weight loss 
• Exercise/Physical activity 
• Substance use: alcohol and tobacco 
• Vaccinations 
• Diabetes control and medications 
 
In accordance with the scope of the present study, this review will mainly focus on HbA1c and other 
selected basic processes of care measures.  
 The American Diabetes Association (ADA) guidelines for standards of care in diabetes
11
 recommend 
biannual determinations of HbA1c in controlled patients; uncontrolled subjects should have this done 
quarterly. Blood pressure should be done at every visit.  Apart from the initial assessment at diagnosis, 
this guideline is not clear on the routine performance of other basic processes such as weight, waist 
circumference and BMI measurements at follow up.  The Society for Endocrinology, Metabolism and 
Diabetes of South Africa (SEMDSA) recommends the following basic processes of care
10 
: 
• HbA1c : biannually if stable; quarterly if treatment changes of treatment goals not achieved. 
• Weight:  done at every visit 
• Waist circumference:  done at very visit 
• BMI:  done annually 
• Microalbuminuria:  done annually if no persistent proteinuria. 
• Blood pressure : done at every visit 
 
Neither the ADA nor SEMDSA  guidelines  recommend routine office determinations of  blood glucose 
levels.   
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2.6.1  Compliance with process of care standards 
Despite the establishment of evidence based guidelines such as those by the ADA and SEMDSA, 
adherence to process of care issues show varying patterns.  In the USA for example, some studies 
estimate the proportion of diabetics receiving care in accordance with ADA guidelines to be less than 
5%.
36,37
  These findings are borne out by larger scale studies examining trends of care over longer 
periods. The study by Saadine et al. assessed changes in diabetes care processes and intermediate 
outcomes for the period 1988-2002 in the United States and reported increases in compliance with 
process of care measures to range from 4% to 8%.
29
 
Some studies in other contexts reveal a different picture.  An audit conducted amongst a sample of 
general practices in Scotland by Guthrie and colleagues showed very high annual testing rates for HbA1c 
(88.1%) and cholesterol (77.8%).
38
  An earlier study, which analyzed data from multiple practices in 3 
health authorities in England, found similarly high proportions of patients who had annual checks for 
HbA1c (83%).
39
  However, both studies reviewed diabetes care in general practice settings that served a 
largely insured population and as such, might not possibly be directly comparable to other contexts.  
Comparable studies in the public sector seem to confirm the trend of below par achievement in 
performance of process measures. One such study conducted in 19  health  centres in the American 
Midwest catering for medically underserved population groups, demonstrated high performance of only 
2 process of care indicators, yearly HbA1c and Lipid monitoring,  at baseline,  before implementation of 
a quality improvement program.
36
  A survey conducted to evaluate diabetes care amongst   First Nation 
populations living in reserves in Alberta, Canada demonstrated that only 46% of the study sample  
reported having met the required standard for frequency of HbA1c testing.
40 
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Research in South Africa points to a similar pattern of unsatisfactory outcomes in basic process of care 
measures in primary and secondary level public health care facilities.  A baseline audit of clinical records 
of 100 Type 2 diabetics attending the outpatients department of a small rural hospital in Kwazulu-Natal, 
revealed that blood pressure and random blood glucose were the only measures routinely recorded;  no 
other diabetic process of care measure, including HbA1c,  was documented.
12 
   Steyn et al., conducted a 
survey to identify provider-related factors in the provision of care to diabetic and hypertensive patients 
attending 18 community health centres in the Cape Peninsula.
15
  Of the 455 diabetic patients’ clinical 
files audited, only 2.6% had an HbA1c measurement recorded in the preceding 12 months.  These 
results for HbA1c measurement contrast significantly with findings of at least one study at a tertiary care 
facility: Van Zyl and Rheeder conducted a quasi-experimental controlled before-and-after study to 
assess the impact of a physician education program on the quality of care in 2 diabetic clinics at a 
tertiary hospital in Gauteng.
13
  At baseline, 65% of the intervention sample and 41.5% of the control 
sample had HbA1c measurements performed in accordance with SEMDSA recommendations; however, 
performance of the other process of care measures studied (foot exam, eye exam, test for micro-
albuminuria and lipid profile) were all significantly below 50% in both groups. 
 
2.6.2  Processes of care and glycaemic control 
There is a substantial body of evidence to suggest that improved processes of care are not necessarily 
mirrored by concomitant improvements in glycaemic control.  Results from a small cross-sectional study 
in 2002 which compared the quality of care received by uninsured diabetics attending private physicians 
to those attending community health centres in a rural area of the United States, found that while 
community health centres performed substantially better on process of care measures, glycaemic 
control did not differ between the two settings.
41
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Subsequent cross-sectional and large scale prospective observational studies that compared processes 
and outcomes have confirmed this finding.
42,43
   Of particular note is the TRIAD study.
43
  In this multi-
centre prospective observational study, one of the questions researchers studied was whether the 
number of documented process of care indicators affected various metabolic outcomes. While the 
addition of one extra process of care measure improved mean LDL levels, no such association was 
demonstrated for effect on HbA1c levels. Intervention and quality improvement studies have similarly 
failed to demonstrate convincing evidence for concordance between process of care indicators and 
glycaemic outcomes
44-47
; in all cases, the interventions significantly improved the processes of care 
investigated without impacting glycaemic control.  Likewise, as in the TRIAD study,  Valk et al., compared 
quality improvement programs for Type 2 diabetics in 2 different countries and reported that  the 
number of HbA1c measurements performed had no impact on long term HbA1c levels.
46
  
Of the South African studies referenced, two attempted to assess the influence of selected processes of 
care on control.
13,15
  In the study by Steyn et.al., the documentation of blood pressure and finger-prick 
glucose readings in patient files  showed no association with glycaemic  control;  however, apart from 
the fact that finger-prick glucose monitoring is not a standard process of care measure,  it is unclear if 
the  levels of performance of either of these processes  met any accepted standard.
15
  Results of the  
quasi-intervention study by Van Zyl and Rheeder which reviewed a  more comprehensive set of 
processes of care, including HbA1c monitoring, appear equivocal: while improvements in the 
performance of processes of care and mean HbA1c in the intervention arm were statistically significant, 
between-group difference in mean HbA1c was not; furthermore, both arms demonstrated non-
statistically significant increments in the proportion of individuals with controlled glycaemia.
13
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Some researchers have tried to make the case for a possible link between processes of care and 
glycaemic outcomes.  For example, in reporting their results of an intervention to improve processes 
and outcomes, Baillie et al., stated that an “increase in monitoring of HbA1c and the use of 
hypoglycaemic agents and insulin was associated with a greater proportion of individuals achieving   
HbA1c < 7%.” 
35
   Whether these factors were individually or jointly responsible was not clear.  Similarly, 
in a cross-sectional survey comparing changes in  the quality of  diabetic care in Norway between 1995 
and 2005, Cooper et al., showed substantial improvement in the performance of a number of processes 
of care, as well as improvements in the proportion of people who achieved  HbA1c <  7%,  but did not  
test the association in multivariate analyses.
48
 However, the researchers noted that trends in HbA1c 
monitoring remained unchanged during the period which would suggest that this process of care was 
probably not responsible for the observed improvements in glycaemic control. 
 
2.7  Weight, diet and exercise 
While obesity has long been recognized as a risk factor for the development of type 2 diabetes5,20,49 , 
there is substantial evidence to show that visceral or intra-abdominal adiposity in particular, is the 
independent risk  factor for insulin resistance which in turn leads to deranged glycaemic control and 
other associated metabolic abnormalities.
50,51
   In light of these findings, it is reasonable to surmise on 
the converse question, i.e., does weight loss in overweight type 2 diabetics lead to improved metabolic 
outcomes?  There is convincing evidence to suggest that this is indeed the case. 
Weight reductions as moderate as 5-10% of baseline body weight  can improve insulin sensitivity
49,52
 
and, consequently,  enhance glycaemic control.  In 2003,  Anderson et al., as part of a larger review and 
meta analysis of trials looking at, inter-alia, the importance of weight management in type 2 diabetes, 
demonstrated a  positive association between weight loss and improved glycaemic control in obese 
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individuals.
53
  The researchers considered all trials over the preceding 30 years conducted on adults with 
a BMI > 30kg/m
2
  or 120% of ideal body weight, who achieved at least a 5% reduction in baseline body 
weight at 12 weeks and concluded that: “Although study protocols and medication regimens differed 
across studies, there was a strong association between weight loss and improved glycemia irrespective 
of the study protocol.”   
Subsequent findings from the Look  AHEAD (Action for Health in Diabetes) study,  a multicentre, 
randomized controlled trial with the  primary objective  of measuring  the impact of long term weight 
reduction on cardiovascular morbidity and mortality in overweight type 2 diabetics, confirmed the 
association between weight loss and glycaemic control.
54,55
   Wing et al.,  reported results of additional 
analyses on the 1-year look AHEAD data.
56
  Amongst others, they reviewed the association between 
HbA1c change and categories of weight loss.  At a moderate weight loss of 5-10%, the odds ratio of 
achieving a 0.5% drop in HbA1c was 3.52.  Equally important is the conclusion that: “The odds of 
clinically significant improvements in most risk factors were even greater in those who lost 10–15% of 
their body weight.”  In particular, the odds for  achieving  a 0.5% decrease in HbA1c in this case was 
5.44.  
 The association between nutrition and glycaemic outcomes appears to be equivocal, a phenomenon 
possibly due to the dearth of research on the independent role of nutrition in the management of Type 
2 diabetes.
57,58
   This  notwithstanding,   in  a 2002 review  by Pastors et al
57
 ,  the authors   concluded 
that, in respect of glycaemic control per se: “Randomized controlled nutrition therapy outcome studies 
have documented decreases in HbA1c of  2% in newly diagnosed type 2 diabetes, and 1% in type 2 
diabetes with an average duration of 4 years.” 
 A systematic review in 2007 by Moore et al
58
, cast some doubt on the efficacy of nutrition as a sole 
intervention in glycaemic control, a finding which they attribute to the lack of high quality data; the 
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researchers were able to conclude that the addition of exercise to nutrition appeared to improve 
glycaemic control in the short term (6 to 12 months). Evidence from at least one, well designed albeit 
small scale randomized controlled trial, suggests that intensive dietary intervention alone in patients 
with type 2 diabetes who also have other CVD risk factors, can achieve HbA1c reductions of 0.4% at 6 
months.
59
 
 Exercise, has been regarded as a key component of diabetes management and, since 1990, 
recommendations for the inclusion of physical exercise as a lifestyle management element have 
continued to evolve due to evidence  that  demonstrates  beneficial effects on both primary prevention 
in individuals at risk for developing type 2 diabetes, as well as on secondary prevention in those with 
established disease.
60
  Results from one of the first systematic reviews that established the beneficial 
effects of exercise on glycaemic control in type 2 diabetics were reported by Boule et al., in 2001.
61
   The 
researchers selected 11 randomized and 3 non-randomized controlled trials where the duration of 
intervention was at least 8 weeks. Meta analysis showed a statistically significant 0.66% (P=0.001) 
decrease in HbA1c in the intervention arms, a result the researchers concluded, “is clinically significant 
and close to the difference between  conventional and intensive glucose-lowering therapy in the  
UKPDS.”  More recent studies not only confirm the benefits of exercise on glycaemic control, but also 
demonstrate that these effects appear to be independent of  exercise modality.
62,63
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2.7.1  Exercise, diet and weight loss advice by healthcare professionals 
Based on mounting evidence for the role of lifestyle factors, not only in the primary prevention, but also 
in the management of type 2 diabetes,   local and international guidelines recommend counseling on 
diet, exercise and weight control as integral components of initial and ongoing management in adults 
with the disease.
52, 64-66
 
Data from a number of large population-based surveys reveal low levels of counseling regarding diet and 
exercise by health-care professionals. Overall rates for counseling on exercise range between 25% and 
42%
67-69
; counseling rates for diet range between 21%  and 37%.
68,69
   
Studies aimed at obese subjects display a variable pattern of counseling.  A 1999 survey by Galuska et 
al., based on data from the 1996 U.S. Behavioural Risk Factor Surveillance System  (BRFSS),  showed that 
42% of obese adults were advised to lose weight.
70
  Even lower rates of counseling were reported in a 
Lithuanian national cross-sectional study by Klumbiene et al., which reviewed receipt of counseling by 
overweight and obese adults from general practitioners.
71
   Twenty three percent of males and 29% of 
females reported having received advice on changing diet; the corresponding rates for exercise advice 
were 16% and 19% for males and females respectively.  However, other studies demonstrated an 
opposing trend.  In a U.S. national survey conducted by Ko et al., 64 % of respondents were told to 
change diet, 86% were advised to increase levels of physical activity and 59% were advised to do both.
72
  
Counseling rates for diet and exercise of 55% and 52% respectively, were noted in a 2011 study amongst 
obese Mexican-Americans by Nguyen et al.
73
  
Concomitant poor health status or chronic medical conditions appear to increase the rate for receipt of 
lifestyle counseling.
68, 69, 72, 74
   More specifically, persons with diabetes have significantly increased odds 
of being counseled.  In the Galuska study cited above, 64% of diabetics reported having been counseled 
on weight loss and the odds for receipt of such counseling was twice that of non-diabetics.
70
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A U.S. population-based survey conducted by Wee et al., showed that, in the overall sample, 34% 
received advice on exercise. Diabetics and patients with cardiac disease had almost twice the odds of 
being counseled as compared to individuals  without  these comorbidities.
67
  
These findings amongst sub-samples of diabetics in general surveys are borne out by research on 
lifestyle advice in diabetics per se.  In a study amongst a nationally representative sample of over 26 000 
adults who, either had or were at risk of, type 2 diabetes, Morrato et al., assessed the prevalence of 
ever having received advice to exercise.
75
  In this  study, more than seventy percent of diabetics were 
told by a health professional to exercise more.  Furthermore, this proportion increased to 76% in 
diabetics who also had heart disease. While this study provides reliable and convincing evidence, a key 
limitation is that it only assessed a single dimension of lifestyle modification. Earlier work by Jorgensen 
et al., researched the question more comprehensively, albeit on a smaller sample, by looking at the 
perceptions of adult diabetics regarding the receipt of counseling on weight, diet, exercise as well as 
diabetic self-management education (DSME).76   Over ninety percent of the participants reported receipt 
of advice on weight reduction and diet, while only 38% reported having received advice on exercise. 
There appears to be a paucity of published data in South Africa on the receipt of lifestyle advice by 
patients with type 2 diabetes. From available studies, the  only one that  considered  the issue, albeit 
briefly and not really as  a key objective of the study, was that by Moodly and Rambiritch which assessed 
diabetes knowledge amongst diabetics attending a primary care facility in KwaZulu-Natal.
14
  Their 
findings appear to contradict the trend of generally high rates of lifestyle advice amongst diabetics 
elsewhere: less than 30% of the sample reported receipt counseling on diet and/or exercise; receipt of 
weight loss advice was not measured. 
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2.7.2  Lifestyle advice and glycaemic control 
Despite its potential for influencing positive lifestyle changes and its recognition as a cornerstone of 
disease management, the impact of self-management education and, in particular, lifestyle counseling, 
on the key outcome of glycaemic control is unclear.  In an extensive systematic review of randomized 
controlled trials that reviewed the effect of self-management education on various outcomes, Norris at 
al., reported that self-management training in general, failed to demonstrate any significant 
improvement in HbA1c.
77
 Similarly, other studies in the same review that specifically focused on lifestyle 
change,  also  failed to show benefit on glycaemic control.  A review of other randomized controlled 
trials that specifically studied the effect of self-management education on glycaemic control, reported 
beneficial effects on HbA1c, but only in the period immediately following the intervention.
78
   In 
particular, the intervention decreased HbA1c by 0.76% more than the control; by 3 months, this 
difference had reduced to a non-statistically significant 0.26%.   However, the more recent DESMOND 
study79, reported in 2008, has cast some doubt on the latter finding. This multicentre randomized 
controlled trial, which  evaluated the impact of a structured , group based education intervention on 
various metabolic and lifestyle outcomes amongst newly diagnosed type 2 diabetics in primary care in 
the UK ,  showed no benefit on HbA1c levels at  4, 8 and 12 months of follow-up.   
There may be a place for individual counseling in particular contexts.  For example, the LOADD study 
demonstrated that intensive, individual dietary counseling over an extended period, could realize 
beneficial drops in HbA1c compared to usual care in type 2 diabetic subjects who were uncontrolled 
despite optimal drug therapy.
59
  Other evidence suggests that specific modes of counseling  may be 
beneficial in a certain subset of patients: in one  systematic review,   face to face counseling,  compared 
to usual care,  showed beneficial effects on glycaemic control in individuals with baseline HbA1c > 8%.
80
    
 
 24 
 
2.8  Diabetic medications 
2.8.1  The need for pharmacological agents 
A clear association between deteriorating glycaemic control and progressive loss of pancreatic β-cell 
function has been demonstrated.
81,82
  A detailed  analysis using homeostasis modeling (HOMA)
83 
 in the 
UKPDS  found that,  within 5 years,   mean β-cell function deteriorated from 50% at diagnosis, to 25%.  
This was reflected in the progression of both FPG and HbA1c which rose at a rate of 2mmol/l and 0.2% 
per year respectively
81
.  In the UKPDS 49
82
 , a three yearly analysis of glycaemic control in the various 
treatment arms of the UKPDS,  only 25% of the combined sample of normal and overweight subjects in 
the diet only cohort   achieved an HbA1c < 7%  in the first 3 years ; by 6 and 9 years, the proportions had 
dropped to 12%  and  9% respectively.  The corresponding proportions in the overweight only arm at 3, 
6 and 9 years were similar. The obvious implication of this is that the initial step of lifestyle modification, 
as advocated by current guidelines10,11, will inevitably prove inadequate and require pharmacological 
modalities for optimizing glycaemic control.84  
The following three classes of anti-hyperglycaemic drugs are currently available for the management of 
type 2 diabetics in the South African public primary health care services
85
: 
• Sulphonylureas ( glibenclamide and gliclazide) 
• Biguanides ( metformin) 
• Insulin ( basal, biphasic and prandial) 
In view of the above, the remainder of this review will mainly focus on these drug classes. 
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2.8.2  Diabetic medication and glycaemic control 
2.8.2.1 The effectiveness of oral agents as mono-therapy 
The  UKPDS was the first large scale controlled trial that clearly demonstrated the effectiveness of oral 
monotherapy in lowering HbA1c.6,7,82   All monotherapy arms achieved significant improvements in 
control: in  the insulin and sulphonyluria  arms of the overall sample, 47% and 50%  of participants 
respectively achieved HbA1c < 7% at 3 years; in the overweight group, the corresponding proportions 
that achieved HbA1c < 7% in the  insulin, sulphonyluria and metformin cohorts were 34%, 45% and 44% 
respectively.
82
   Additionally, these figures were significantly better than that achieved with diet alone 
where, in the combined sample of normal and overweight individuals, 25% achieved HbA1c < 7%.   As 
part of an in-depth systematic review of oral antihyperglycaemics, Inzucchi looked at a number of RCTs 
that investigated the efficacy of oral monotherapy, as compared to diet or placebo, in reducing HbA1c.
84
 
In trials with sulphonylureas, the percentage drop in HbA1c ranged from 0.9 to 2.5%. The corresponding 
percentage drop in trials involving metformin ranged from 0.8 to 3.0%.  Results  from  trials of head-to-
head comparisons, showed overall equivalent efficacy of these drugs.  Furthermore, the author noted 
that:   “Only sulphonylureas and metformin have been shown to reduce microvascular complications 
with metformin exhibiting additional benefits on macrovascular risk.”
84 
2.8.2.2  The need for additional drugs 
After 9 years of follow-up, all treatment arms in the UKPDS showed significant decline in glycaemic 
control as evidenced by both,  the mean FPG levels,  as well as  the proportion of patients with HbA1c < 
7%.
81,82
   The association of deteriorating β-cell function in this regard has been noted above.  This 
phenomenon of secondary failure, defined as: “a switch or addition of antihyperglycaemics when the 
existing treatment fails to sustain adequate control”
86,87
,  has been demonstrated for oral anti-
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hyperglycaemics  in other studies.
88,89
   Alvarsson et. al., conducted a 2-year prospective study in Sweden 
to compare insulin and sulphonylurea in their effects, inter alia, on metabolic control.
88
   After  one year, 
both treatment arms showed improvements in HbA1c but, by the end of the study period, the 
sulphonylurea arm experienced significant worsening of HbA1c levels.  Results in this study were limited 
by the use of small sample sizes (n=21 and n=18 in the sulphonylurea and insulin groups respectively) 
and the short follow up period.   
In the ADOPT study, which was a multicentre RCT comparing treatment efficacy of thiazolidinediones 
with that of metformin and glyburide (a sulphonylurea),  proportion of patients that had controlled 
glycaemia ( HbA1c < 7%)  after 4 years in the latter two cohorts was 36% and 26% respectively.  
Incidence of secondary failure in the these two treatment cohorts  was 21% and 34% respectively; yearly 
failure rates were estimated to be approximately 4% per year.90  
Secondary failure of metformin was investigated in an observational cohort study by Brown, Connor and 
Nichols amongst 1 799 patients in a clinical setting who started metformin as their first line oral 
therapy.
89
  Clinical data was analyzed for a follow up period of up to 5 years. Within a mean follow up 
period of under 28 months, secondary failure was demonstrated in 44% of subjects; the annual failure 
rate was estimated at 17% per year.   In a large scale retrospective study of the effectiveness of oral 
treatment in Type 2 diabetics,  Boccuzzi et al., demonstrated  12-month secondary failure rates of  22% 
and 19 % for metformin and sulphonylureas  respectively.
86
  A key strength of these two studies is that 
they investigated failure rates in real world clinical practice settings and the findings , specifically in the 
Brown et al., study, suggest that failure rates  might be higher than those reported in clinical trials. 
89,90
  
Given the clear risk of treatment failures of both suphonylureas and metformin monotherapy, as well as 
the fact that these agents target different glycaemia lowering pathways, combination oral therapy is a 
plausible strategy in achieving glycaemic control.  Convincing evidence for the efficacy of this approach 
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was provided by a supplementary trial of the UKPDS which reviewed the effect of adding metformin to 
sulphonylurea.
7
 In reviewing the evidence for the efficacy of combination oral therapy, Inzucchi 
concluded that: “Each clinical trial that has examined the addition of an oral
 
agent to that of another 
class has demonstrated additive HbA1c
 
reduction.  With few exceptions, the effect on HbA1c has been 
similar to the effect from using
 
the added drug as monotherapy vs placebo.” 
84
 
2.8.2.3   Adjunctive insulin therapy  
Failure of oral monotherapy to achieve glycaemic control necessitates the addition of a second agent, 
and current guidelines commonly recommend the addition of a second oral agent.10,11,66   However, β-
cell function continues to decline in the face of dual therapy with sulphonylureas  and metformin91 since 
neither agent appears to preserve pancreatic secretory function and the former might even be 
detrimental to β-cells.92  
The continued decline in glycaemic control after the addition of a second oral agent was demonstrated 
by Cook et al who conducted a retrospective analysis on medical records of  patients in United Kingdom 
primary care practices.
93
  Their sample comprised 2 200 individuals who commenced monotherapy with 
metformin before augmentation with sulphonylureas.  Median HbA1c at baseline was 8.8% and, 76% of 
the sample had HbA1c > 8.0%.  The lowest median HbA1c occurred at 6 months post-sulphonylurea 
augmentation, after which HbA1c started to deteriorate at a rate comparable to that prior to 
sulphonylurea augmentation.  Given this deterioration, 85% of their sample was projected to reach 
HbA1c levels > 8.0% within 4 years. 
The efficacy of combined insulin and oral therapy in the improvement of glycaemic control compared 
with either insulin monotherapy  or combination oral therapy has been studied.   One of the early trials 
was conducted by Yki-Jarvinen et al., amongst Nordic diabetics attending  out-patient  department 
clinics 
94
.  A sample of 96 patients,  poorly  controlled on a sulphonylurea, were randomized into  groups 
 28 
 
on various combinations involving metformin,  sulphonylurea  and  basal insulin, including one  arm on 
insulin only.  At the end of 1 year, the cohort on combined therapy with insulin and metformin displayed 
the greatest improvement in HbA1c: from 9.7% at baseline, to 7.2%.  
 Two systematic reviews, one by Yki-Jarvinen
95
, and the other by Burke
96
 reviewed the evidence for 
combination oral and insulin therapy.  In the Yki-Jarvinen review, out of 15 studies, 10 demonstrated 
similar glycaemia lowering efficacy between the combination and insulin only cohorts; in 4 studies, the 
combination arm was superior.
95
   According to the later Burke review, while there was evidence for the 
superiority of combined therapy with insulin and metformin over insulin alone,  the  potential of 
realizing  a similar advantage by substituting metformin with other classes of oral agents was unclear.
96
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2.9  Conclusions 
This review highlights a number of important findings relevant to the context of the present research. 
Key amongst these are: 
• Prevalence of type 2 diabetes has reached epidemic proportions worldwide; recent estimates 
suggest that prevalence, both globally and in South Africa, will double by 2030. 
• Pathologic effects seen in the disease are mainly due to micro- and macro-vascular 
complications.  Research has clearly established the link between glycaemic control and micro-
vascular pathology ; the association with macro-vascular pathology appears equivocal. 
• Levels of glycaemic control are unsatisfactory with estimates of controlled glycaemia varying 
between 20% and 50%. Available data for SA suggest that levels of control might be as low as 
10% and no better than 30% (inconsistent use of definitions of glycaemic control is a major 
drawback for comparison). 
• Compliance with standards for processes of care, while displaying high levels of achievement in 
some settings, appear to be generally inadequate.   
• Compliance with process of care standards, and particularly that for HbA1c monitoring, do not 
necessarily realize  commensurate  improvements in glycaemic control.  
• There is convincing evidence to suggest that weight loss and exercise promote glycaemic  
control;  nutritional interventions only appear to be effective in this regard when combined with 
exercise. 
• While rates of counseling by health professionals on weight loss, exercise and diet are low in 
most contexts, the presence of co-morbidities in general, and diabetes in particular, appear to 
increase the odds of receipt of such counseling.   
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• With the possible exception of particular modes of   counseling in specialized groups of patients, 
the effect of lifestyle advice on glycaemic control is uncertain. 
• There is a substantial body of compelling evidence demonstrating both the efficacy of, as well as 
the necessity for, anti-hyperglycaemic drugs in achieving glycaemic control. In particular, both 
classes of oral medications available in the South African public primary health care sector are 
effective as mono- and dual therapy.   However, the progressive failure of pancreatic secretory 
function  requires  augmentation with insulin.  Except possibly for the combination of insulin and 
metformin,  evidence for the superiority of combined insulin and oral therapy over insulin 
mono-therapy   is unequivocal.  In addition to its synergism with insulin in glycaemic control, 
metformin has the added benefit of improving other metabolic parameters. 
 
Processes of care, delivery of lifestyle advice and pharmacological treatment represent a cluster of 
factors that describe what clinicians do as part of an overall management plan to achieve specific quality 
and metabolic outcomes in individuals with type 2 diabetes mellitus.  While there exists a plethora of 
research that studied either of these factors, there appeared to be none at the time of the current study 
that comprehensively investigated all three.  This lack of a comprehensive consideration of these factors 
is likewise reflected in studies that assessed their impact on glycaemic control.   The latter shortcoming 
is particularly notable in South African research.    At the time of the present study, the influence of key 
process of care parameters such as HbA1c monitoring, the provision of lifestyle advice by healthcare 
professionals, and pharmacological treatment, either individually or in combination, on glycaemic 
control amongst individuals with type 2 diabetes attending a public primary health care facility is largely 
unknown.  A key objective of the present study was to address this important gap in the corpus of 
current research.  
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CHAPTER 3 
METHODOLOGY 
_____________________________________________________________________________________ 
3.1  Study design 
A cross-sectional design was used in this study. This particular design is subsumed under the general 
class of observational studies that have a descriptive component which facilitates calculations of 
prevalence figures for exposures and outcomes, as well as an analytical component which allows cross-
classifications between exposures and outcomes for the purpose of statistical investigation of possible 
relationships between these.
97
   
 
3.2  Study setting 
The study was conducted at the Johan Heyns Community Health Centre (CHC), one of two large primary 
health care (PHC) facilities in the Emfuleni sub-district of the Sedibeng District, Gauteng Province. 
Located approximately 75 km south of Johannesburg, this health centre has an estimated catchment 
population of 70 000, mainly black and white uninsured patients both from the town itself, as well as 
from surrounding areas.  In addition to offering a full range of PHC services, the facility also serves as the 
referral centre for five smaller PHC clinics in the area.  
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3.3  Study population 
All adults 18 years and older, with type 2 diabetes attending  the Johan Heyns CHC for treatment at the 
time of the research formed the study population. 
3.4  Sampling 
3.4.1  Sample size 
Since a key objective of this study was to estimate the prevalence of glycaemic control, this parameter 
was used to determine an appropriate sample size.  Studies elsewhere  suggest that glycaemic control 
appears to be no better than 47% 
29,31,32
 , while the local study by Steyn et al., found 24% of their sample 
to have controlled glycaemia.
15
  Results from a  previous audit at the  site of the present study suggested 
that  glycaemic control  was approximately 30%.
18
 
 Given these observations, a hypothesized value for glycaemic control in the present study was set at 
30%.  Furthermore, the power of detecting a prevalence of glycaemic control within + 10% of the 
hypothesized value, with a significance level of 0.05, was set at 80%. The relevant formulae for 
determining the minimal sample size under these assumptions is discussed in Kirkwood and Sterne 
(2005).
98
   Calculations, conducted with the aid of Stata release 12 (StataCorp LP, College Station, Texas, 
USA) statistical software, yielded a sample size of 153.  In addition, the calculated sample size was 
adjusted to mitigate for possible effects of loss to follow-up or non-response.   If a potential loss to 
follow-up of 20% is assumed, then the appropriate adjustment factor that the calculated sample must 
be multiplied by is 1.25.
98
  This resulted in the adjusted sample size of 153x1.25 = 191.25 participants.  
Based on this, and for ease of data analysis, a final sample size of 200 was chosen. 
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3.4.2  Sampling strategy 
An appropriate sample was drawn from a sampling frame consisting of all adults with diabetes who are 
patients at the facility.  The inclusion and exclusion criteria were as follows: 
• Inclusion criteria: 
o Adults 18 years or older presenting at the facility for routine  diabetic care . 
o A diagnosis of type 2 diabetes for at least 12 months  as indicated in clinic records. 
o Must have had at least 2 clinic encounters for diabetes management in the last 12 
months 
o Participant ability  to understand and respond to interview questions in any of the 4 
major languages spoken in the area: Sotho, Zulu, Afrikaans and English 
o Ability to voluntarily give written, informed consent 
• Exclusion criteria: 
o Failure to meet any inclusion criterion 
o Any patient managed at another facility and attends the study clinic to collect 
medications only.  
o Any medical emergency, mental incapacity or pregnancy 
 
Participants were recruited through the following consecutive sampling strategy: 
Chronic visits at the study facility are booked daily from Mondays to Thursdays, excluding public 
holidays.  Daily, clinic records of all chronic patients with appointments for the next day are arranged in 
the admissions area by admissions personnel.  Records of adult patients with diabetes, whose numbers 
range between 5 and 15 per day, were inspected by the researcher for compliance with all inclusion 
criteria except those pertaining to voluntary consent and language requirements. All eligible records 
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were then set aside and each of these patients was consecutively approached for participation in the 
study on the morning of their appointment.  At this time, the remaining selection criteria were applied 
to determine final eligibility and, whenever an individual was excluded on this basis, the next person in 
the sequence was considered.  
Participant recruitment was conducted by two PHC nurses, who were appropriately trained to do this.  
Sampling occurred daily from Monday to Thursday and was continued until attainment of the desired 
sample size. 
 
3.5  Measuring tools 
Two measurement tools were used to collect the required information.  The first was a close-ended 
questionnaire used to interview study participants for socio-demographic information, lifestyle and 
information relating to other patient factors (Appendix A).  Variables measured were: 
• Socio-demographic data: date of birth, gender, residence, employment, educational level. 
•  Diabetes duration. 
• Diabetic self management information: receipt of advice  from a health worker on one or more 
of the following:  
o weight control 
o exercise 
o diet 
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In addition,  anthropomorphic measurements  comprising   waist circumference (WC) and, for the 
purpose of calculating  BMI, height and weight,  were done at the time of the interview  and recorded on 
this document. Information regarding performance of process of care elements and diabetic treatment   
was extracted from patient records using a separate data collection sheet (Appendix B).   
 For processes of care elements in this study, variables measured reflected the performance frequency 
in the preceding 12 months of the following: 
• BP montoring 
• HbA1c monitoring 
• BMI measurement 
• Weight and WC measurement 
In addition to the above, BG monitoring, although not a recognized core process of care element in local 
guidelines
10
, was also recorded. 
For information on diabetic treatment, the current pharmacological treatment, as recorded in the 
prescription charts, was used.  Also extracted from clinical records was information on co-existing 
medical conditions. 
The main outcome, current glycaemic control, was assessed as follows:  
• If available, the latest HbA1c value not older than 1 month was used. 
• Where this was not available, participants were requested to have blood drawn for an 
HbA1c test after the interview. 
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3.6  Data collection 
Data collection was accomplished in 2 stages.  The first stage occurred during the recruitment process 
and was carried out voluntarily by 2 trained PHC nurse clinicians.  During this phase, all eligible 
individuals who initially agreed to participate, were taken to a separate clinical area where each was 
briefed on the purpose and contents of the study, ethical issues were explained and voluntary consent 
sought.  The interview questionnaire was then administered to each participant after signed consent 
was obtained.  Following this, all participants, even those that declined consent after being briefed, 
were attended to by the researcher for their usual medical care and thereafter had blood drawn for 
HbA1c according to the criteria stated in 3.5 above.   Also measured here were parameters for the 
anthropomorphic profile which was done in accordance with current guidelines from the National 
Department of Health.
99
 
The second stage of data collection consisted of a record review of all  consenting  participants’ clinical 
files for the purpose of extracting information in respect of process of care elements, treatment details 
and other clinical data described in 3.5 above . Since this also required the recording of the latest HbA1c 
results in cases where blood was drawn during the first stage, all information for the second stage was 
collected by the researcher at a convenient time after the first stage.  
 For the purpose of later access to clinical records, which are stored at the facility, each participant’s 
clinic reference number was recorded on the interview sheet; this reference was later expunged once 
the required information from the relevant clinical record had been abstracted. 
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3.7  Data analysis 
All analyses were conducted by the researcher using Stata release 12 (StataCorp LP, College Station, 
Texas, USA) statistical software. Descriptive statistics were used to summarize all measured variables.  
Means and medians were the descriptive measures for continuous variables while proportions and 
frequencies were the summery measures for categorical data. Comparison of means was carried out 
using analysis of variance (ANOVA) and, where this was precluded due to non-homogeneity of variances, 
a non-parametric test, the Kruskal-Wallis rank test, was applied.  Where deemed appropriate, 
continuous data was re-coded as categorical data and analyzed accordingly.  Associations of glycaemic 
control were initially explored through univariate  analysis, using  χ2  ( chi-squared)  methods to identify 
possible outcome predictors from amongst the  explanatory variables measured;  subsequently, all 
significant covariates were  subjected to  univariate logistic regression  analysis  to derive crude odds 
ratios for strengths of association.  Finally, composite parsimonious explanatory models with adjusted 
odds ratios for glycaemic control in this study were   constructed through multivariate stepwise logistic 
regression.  
 A  2-tailed P < 0.05 was considered to be statistically significant for measures of association  and the 
probability level for  statistical significance of confidence intervals was set at 95%.   
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3.8  Pilot study 
After the required approvals for conducting the research were secured, a pilot study was undertaken at 
the research site prior to actual data collection to: 
• Refine the quality and structure of the questionnaire as well as uncover potential problems 
regarding sensitivity of questions. 
• Ensure uniformity in the administration of  questionnaires by the fieldworkers 
• Assess the feasibility of the sampling procedure 
• Address other logistical issues such the average time taken for each interview and other 
potential inconveniences to participants 
A small sample of 10 participants who satisfied the required criteria were chosen for the pilot study. 
These individuals were excluded from the final study sample. 
 
3.9  Study bias 
In general terms, bias is the “deviation of results or inferences from the truth” 
100,101
.  Specifically, in the 
research process, bias refers to any “trends in the collection, analysis and interpretation” of information 
that can lead to such deviation.
100
 
A number of potential biases were identified in the present study.  
3.9.1   Sampling  and selection bias 
Selection bias results when there are systematically differing characteristics in those that agree to 
participate in the study compared to those that decline.  Sampling bias results from systematic errors 
induced by non-random sampling methods. 
100
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 The sampling strategy adopted in this study took account of all potential candidates on each data 
collection day to minimize any bias due to adoption of a specific sampling procedure.  However, since 
participation in the study was entirely voluntary, selection bias on account of non-participation was 
unavoidable.  In particular, some of those who refused to participate might have done so for reasons of 
employment, and non-participation of such individuals would entail the obvious effect of 
underestimating the proportion of employed individuals in the final study sample. Finally, there is the 
question of individuals who presented at the facility on Fridays. Since no patients are routinely booked 
for Friday chronic care visits, it is reasonable to surmise that these individuals  presented at this time for 
extraordinary reasons such as an emergency, and if so, would necessarily be excluded on account of the 
preset exclusion criteria. Alternatively, if these patients presented on Fridays for reasons other than 
those precluding them from inclusion based on the set exclusion criteria, bias in certain outcome 
measures is unavoidable. 
3.9.2  Interview and measurement bias 
Systematic errors induced by conscious or subconscious selectivity in information gathered by 
interviewers is termed interview bias , while measurement  bias  is said to occur when such errors result 
from inaccurate measurements of study variables.
100
  
To minimize interview bias, both fieldworkers, PHC trained nurse clinicians of similar standing and 
experience, were trained in the administration of the interview questionnaire.  Also during this stage, 
anthropomorphic measurements were performed and, to facilitate uniformity in this process, the field 
workers were trained to conduct these in a standardized manner according to   accepted guidelines
99
   
using the same tape measure and the same, combined height and weight, measuring scale for all 
participants.  Problems arising from both these data gathering procedures were identified and 
addressed in the pilot study.  Nonetheless, the possibility of operator induced interview or 
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measurement bias cannot be entirely excluded; however, there was no a priori reason to suppose that 
any such error was dependent on the main outcome of this study and, consequently, any 
misclassification here is likely to be non-differential.  
3.9.3 Recall, reporting and information biases 
Any inaccuracies or incompleteness in memory recollection that result in systematic errors is referred to 
as recall bias100; reporting bias, on the other hand, occurs when respondents either suppress, or 
selectively volunteer information.100 
During the interview stage, participants were expected to recall any lifestyle advice they might have 
received in the preceding twelve months and each one was also asked when they were first diagnosed 
with diabetes. In both these instances, differential misclassification based on information recall cannot 
be excluded.  Furthermore, in the former instance, there is the added possibility of reporting bias: 
participants could have volunteered information that they believed the interviewers wanted to hear. 
Since record reviews are limited by the quality of information recorded therein, any data abstracted 
here is also subject to measurement bias.  Where it was not possible to reliably ascertain details of 
treatment and co-morbidities due to either incomplete or missing records, such records were excluded 
during analyses involving these variables and any bias in this regard cannot be avoided.  These records 
were, however, small in number compared to the overall sample size and as such were not expected to 
exert a significant influence on the outcomes studied. 
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3.10  Ethical considerations 
Prior to the commencement of this study, ethical approval was sought and obtained, clearance number: 
M 080635 (Appendix C), from The University of the Witwatersrand Human Research Ethics Committee     
(Medical). Permission to conduct the research at the study site was obtained from the Sedibeng district 
health management (Appendix D). 
  Participation in the study  was  completely voluntary, subject to prior informed consent and, the right 
of any participant to withdraw at any point , was respected at all times. To this end, an information 
sheet detailing the nature of the study, the data sought both, during the interview, as well as the record 
review stages, and the rights of participants during the data collection process (Appendix E), was 
attached to each interview questionnaire and explained to all participants prior to obtaining written 
consent; the latter was captured on a separate form (Appendix F) also attached to each questionnaire. 
Participant identification details were recorded during each initial interview to facilitate subsequent 
linkage to the relevant patient clinic file for the purposes of the record review; following the latter, all 
data was entered anonymously into a computer database for subsequent storage and analysis.  
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CHAPTER 4 
RESULTS 
____________________________________________________________________________________ 
4.1 Introduction 
The structure of this chapter comprises three broad sections.  First, a description of the various 
parameters investigated in this study is given using the appropriate descriptive statistical measures.  
Following this, results of univariate analyses of associations with glycaemic control are presented.  Here, 
results pertaining to the core parameters of this study viz., processes of care, lifestyle advice and drug 
treatment will be presented in detail. Finally, logistic models for glycaemic control in this study are 
constructed using, as explanatory variables, all parameters found to be statistically significant on 
univariate analysis.  All results are depicted by means of tables, with additional statistical and other 
relevant information appended as appropriate.   
4.2 Final sample size and missing data  
Recruitment occurred over a period of approximately 6 weeks and a total of 200 individuals who met 
the inclusion criteria and consented to interview, constituted the final study sample. No record was kept 
of people who declined to participate.   
Missing data was encountered during the various stages of the data collection process so that the totals 
for some parameters will not always equal 200.  During the interview phase, all patients in the sample 
had blood drawn for HbA1c.  However, results were unavailable for 8 patients and this was due to the 
laboratory not processing these samples on account of missing information on the blood test forms 
(missing clinician MP numbers). Consequently, HbA1c data was available for 192 patients in the sample.   
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Also, during this phase, education level was not recorded in 1 questionnaire, 7 patients couldn’t 
remember when they were diagnosed with diabetes  and,  information on  patient’s sex was either 
missing, or not clearly recorded,  in 6 interview questionnaires.  In the record review phase, 7 patient 
files could not be located which resulted in process of care information   being available for 193 patients.   
A further 2 files had either missing, or incomplete information on drug treatment and co-morbid 
conditions.  
 
4.3 Demographics 
Demographic characteristics measured in this study are shown in table 4.1 below.   
Participants’ ages ranged from 20 years to 84 years with a mean of 57.76 years (SD= 9.960); (95%CI: 
56.37; 59.14).   Blacks, females and people in the 50-64 year age group made up the majority of the 
sample. Mean ages of females and males were 56.67 and 59.79 respectively and the difference between 
these means was statistically significant (p = 0.034). 
Vanderbijlpark, which is the catchment area of the facility, had just over a quarter of the patients. With 
the exception of Evaton and Residensia, patients from outside the catchment population lived in 
townships   surrounding  Vanderbijlpark, mainly  Bophelong, Sebokeng, Boipatong and Sharpeville.  
Most individuals (87.4%), had some form of education, mainly at the secondary level while a small 
minority reported having completed either matric or tertiary education. 
Just  under 60% derived income from either from some form of employment, or a state pension. Four 
individuals did not specify their source of income.  Almost 41% reported being unemployed and having 
no other source of income. 
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Table 4.1 Demographic characteristics of the study sample 
Demographic Parameters Categories Frequency % 
Age Group 
(n = 200) 
Under 35 3 1.5 
35-49 31 15.5 
50-64 115 57.5 
65-79 49 24.5 
80+ 2 1 
Total 200 100 
Sex 
(n = 194) 
Female 122 62.89 
Male 72 37.11 
Total 194 100 
Race 
(n = 200) 
Black 175 87.5 
Indian 1 0.5 
White 24 12.0 
Total 200 100 
Residence 
(n = 200) 
Catchment Area 53 26.5 
Outside Catchment 147 74.5 
Total 200 100 
Education 
(n = 199) 
Primary 68 34.2 
Secondary 95 47.7 
Matric 8 4 
Tertiary 3 1.5 
None 25 12.6 
Total 199 100 
Employment Status 
(n = 200) 
Unemployed 81 40.5 
Pensioner 59 29.5 
Employed 56 28 
Unspecified 4 2 
Total 200 100 
 
 
4.4 Clinical information 
4.4.1 Duration of diabetes and presence of co-morbid conditions 
Time since diagnosis of diabetes ranged from 1 to 34 years, with a mean (SD) and median of 7.97 (5.56) 
and 7 years respectively.  Almost 95% reported having diabetes for less than 20 years and the majority 
of these had the condition for less than 10 years.  The vast majority of patients had at least one co-
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morbid condition with hypertension by far the commonest, followed by CCF.  Apart from these, 8 other 
co-morbidities were identified and combined into a single category. These observations are depicted in 
table 4.2 below 
Table 4.2 Duration of diabetes and presence of co-morbidity 
Clinical parameter Categories Frequency % 
Duration of Diabetes (years) 
(n= 193) 
Less than 10 131 67.88 
10 – 19 54 27.98 
20 – 29 7 3.63 
More than 30 1 0.51 
Total 193 100 
Presence of Co-Morbid 
Condition 
(n = 191) 
Present 177 97.7 
Absent 14 2.3 
Total 191 100 
Co-Morbid Condition by 
Disease Type 
(n = 191)* 
Hypertension 176 92.15 
CCF 19 9.95 
Other 16 8.32 
* Totals here don’t up to 191 and 100% since some patients had > 1 condition 
 
4.4.2  Anthropomorphic profile 
 Anthropomorphic measurements of the sample are shown in table 4.3 below.   BMI values ranged 
between 20.2 and 64.21kg/m
2
 with a mean of 33.51kg/m
2
 (95% CI: 32.51; 34.51); median BMI was 
31.88kg/m
2
.  By BMI category, the majority were either overweight or moderately obese.  
Waist circumference ranged from 72-144cm; the mean and median values of this parameter were 
106.69cm (95% CI: 104.88; 108.52) and 107cm respectively. Amongst either sex, the overwhelming 
majority had a WC that placed them at substantial cardio-metabolic risk.   
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Table 4.3 Anthropomorphic profile 
Anthropomorphic  
Parameters 
Categories Frequency % 
BMI (kg/m
2
) 
(n =200) 
< 18 
(Underweight) 
0 0 
18.5-24.9 
(Healthy) 
11 5.5 
25-29.9 
(Overweight) 
59 29.5 
30-34.9 
(Moderately Obese) 
 
62 31 
35-39.9 
(Severely Obese) 
 
36 18 
>40 
(Morbidly Obese) 
32 16 
Total 200 100 
Waist Circumference (cm): 
Females 
(n = 122) 
< 80 
(Normal Risk) 
1 0.82 
> 80 
(Increased Risk) 
5 4.10 
> 88 
(Substantial Risk) 
116 95.08 
Total 122 100 
Waist Circumference (cm): 
Males 
(n = 72) 
< 94 
(Normal Risk) 
17 9.28 
> 94 
(Increased Risk) 
10 7.73 
> 102 
(Substantial Risk) 
45 82.99 
Total 72 100 
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4.5  Processes of care 
The vast majority of patients’ blood pressure measurements were done in accordance with the required 
standard.  Although 4 patients had their height recorded at least once during the preceding 12 months, 
only 3 patients had their BMI measured.  None of the sample had their weights recorded monthly; this 
did not however prevent BMI determinations since, according to the standards used, the BMI need only 
be done once in 12 months.  Apart from that for blood pressure measurements, less than 2% of the 
patient records fulfilled the required standards for the remaining process of care measures. The 
following table depicts these findings. 
Table 4.4 Proportion of sample whose medical record met the standard for the selected 
processes of care 
Processes of care Frequency (n=193) % 
Blood Pressure measurement 180 93.26 
Weight 0 0 
HbA1c 3 1.55 
BMI 3 1.55 
WC 0 0 
 
In addition, 76.7% of the clinical records had a finger-prick blood glucose recorded at every routine 
diabetic visit 
4.6  Receipt of lifestyle advice 
The proportions of individuals who received advice on exercise, diet and weight control from a health 
worker are shown in table 4.5 
Most patients reported having received advice on at least one of these self-care parameters.  For those 
who reported advice on at least one of the topics (n=158), responses were further categorized to 
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determine what combinations of topics advice was received on.  As shown in table 4.5, only a minority 
reported advice receipt on just one or two topics; the majority reported advice on all three.  No 
participant reported receiving advice on exercise alone or weight control alone. 
Table 4.5 Reported receipt of lifestyle advice on diet, exercise and weight control 
Advice Combinations Frequency ( n=158) % 
Diet, exercise and weight 127 67 
Diet alone 14 7 
Diet and weight 8 4 
Exercise and diet 8 4 
Exercise and weight 1 0.5 
No advice 42 21 
Total 200 100 
 
 
4.7  Pharmacological management 
 An overwhelming majority, 95.29%, were prescribed oral drugs either alone or in combination with 
insulin. The various   combinations by treatment type are shown in table 4.6.  
Table 4.6 Prescribed diabetic medications by treatment type  
Treatment type combinations Frequency (n = 191) % 
oral only 120 62.83 
oral and insulin 62 32.46 
insulin only 9 4.71 
Totals 191 100 
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The breakdown of treatment combinations by medication class is shown in table 4.7.  Metformin was 
the most commonly prescribed drug class with the majority on a combination of metformin and 
sulphonylurea.   Slightly less than 20% of the sample was on a single medication class.  Insulin was most 
commonly combined with metformin.  
Table 4.7 Prescribed diabetic medications by medication class 
Medication class combinations Frequency  (n = 191) % 
metformin + sulphonylurea 93 48.69 
insulin + metformin 30 15.71 
insulin + metformin + sulphonylurea 27 14.14 
metformin only 21 10.99 
insulin only 9 4.71 
sulphonylurea only 6 3.14 
insulin + sulphonylurea 5 2.62 
Totals 191 100 
 
4.8  Glycaemic  control 
For the available data (n=192), HbA1c values ranged from 4.8% to 14.6% with a mean and median of   
8.55% (95% CI: 8.25; 8.86) and 8.4% respectively.  The proportions of patients with  controlled and 
uncontrolled glycaemia are shown in the table 4.8. Only a quarter of the sample had controlled 
glycaemia 
Table 4.8 Proportions of the study sample with controlled and uncontrolled glycaemia 
HbA1c Frequency (n = 192) % (95% CI) Mean HbA1c 
 
Median HbA1c 
< 7% 
(Controlled) 
47 24.48  ( 18.6 ; 31.2 ) 6.11 
 
6.1 
> 7% 
(Uncontrolled) 
145 75.52  ( 68.8 ; 81.4) 9.3 
 
9.0 
Totals 192 100 
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As demonstrated by their respective 95% CI’s, the difference in the proportions between those with and 
without controlled glycaemia was statistically significant. The difference in mean and median HbA1c 
between the 2 groups was also statistically significant (ANOVA and Kruskal-Wallis: P = 0.00) 
Glycaemic control was further classified using the definitions of control in the ACCORD trial
102
, as shown 
in the following table: 
Table 4.9 Profile of glycaemic control delineated by the ACCORD criteria  
Classification Frequency 
(n = 192) 
% 
(95% CI) 
mean 
HbA1c 
median 
HbA1c 
Optimal target 
(HbA1c <7) 
47 24.5 
(18.6 ; 31.2) 
6.11 6.1 
Standard target 
(HbA1c : 7- 7.9) 
39 20.3 
(14.9 ; 26.7) 
7.37 7.7 
Poor control 
(HbA1c > 8) 
106 55.2 
(47.9 ; 62.4) 
10.06 10.9 
Totals 192 100 
 
A statistically significantly higher proportion of the sample was classified as poorly controlled as 
compared with those who had optimal or standard control while the differences in proportions in the 
latter 2 categories were not.  All differences in mean and median HbA1c between the 3 categories were 
statistically significant (ANOVA and Kruskal-Wallis: P = 0.00). 
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4.9  Univariate  associations  of glycaemic control 
In this and all subsequent analyses of glycaemic control, controlled glycaemia is defined as HbA1c < 7%; 
this corresponds to the “optimal target” definition in ACCORD.
102
 
4.9.1  The processes of care 
 Since none of the patient records met the process of care standard for weight and WC measurement, 
these parameters could not be tested for association.  Of the remaining   processes of care parameters, 
none attained statistical significance for glycemic control.  However, a pattern of lower proportion of 
control is present amongst those in whom the standard for HbA1c and blood pressure monitoring was 
attained. These findings are depicted in the tables below: 
Table  4.10 Blood pressure monitoring and glycaemic control 
Monthly Blood Pressure monitoring % controlled % uncontrolled 
standard attained 23.70 76.30 
standard not attained 30.77 69.23 
                             Pearson χ
2
 = 0.3295, p = 0.566 
Table  4.11 HbA1c  monitoring and glycaemic control 
HbA1c monitoring % controlled % uncontrolled 
standard attained 0 100 
standard not attained 24.49 75.41 
                                          Pearson χ
2
 = 0.9731, p = 0.324 
Table 4.12 BMI monitoring and glycaemic control 
BMI monitoring % controlled % uncontrolled 
standard attained 33.33 66.67 
standard not attained 24.04 75.96 
                                          Pearson χ2 = 0.1389,   p = 0.709 
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4.9.2  Lifestyle advice on diet, exercise and weight control 
None of the topics of lifestyle advice showed a statistically significant association with control.  As the 
tables below demonstrate, there was a trend toward lower proportion of control amongst participants 
who reported receiving advice.  
Table 4.13 Exercise advice and glycaemic control 
Exercise Advice Received % controlled % uncontrolled 
yes 22.14 77.86 
no 29.51 70.49 
          Pearson χ
2
 = 1.2231,   p = 0.269 
 
Table 4.14 Dietary advice and glycaemic control 
Diet  Advice Received % controlled % uncontrolled 
yes 22.37 77.63 
no 32.50 67.50 
             Pearson χ
2
 = 1.7583,   p = 0.185 
 
Table 4.15 Weight control advice and glycaemic control 
Weight Control Advice Received % controlled % uncontrolled 
yes 22.90 77.10 
no 27.87 72.13 
             Pearson χ
2
 = 0.5557,   p = 0.456 
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To assess the joint effect of advice received , a binary categorical variable was defined containing the 
following categories: “no” if no advice was reported on any of the topics, and “yes”  if any advice was 
reported  on one or more topics.  Again, as depicted in table 4.16 below, the association with control 
was not statistically significant but the trend of higher proportion of control amongst  those reporting no 
advice was preserved: 50% more individuals were controlled amongst those that received no advice 
compared with those that received any advice. 
Table 4.16 Receipt of any advice and glycaemic control 
Any Advice Received % controlled % uncontrolled 
yes 22.22 77.78 
no 33.33 66.67 
              Pearson χ
2
 = 2.0754,   p = 0.150 
 
4.9.3  Drug treatment 
Associations of drug treatment with glycaemic control were tested, first using treatment types, and 
thereafter, using medication classes as explanatory variables.  Outcomes of these analyses are displayed 
in tables 4.17 and 4.18 below. 
Table 4.17 Diabetic treatment type and glycaemic control 
Treatment Type Combination % controlled % uncontrolled 
oral only 30.70 69.30 
insulin only 44.44 55.56 
oral and insulin 14.9 46.1 
                                  Pearson χ
2
 = 11.4105,   p = 0.003 
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Table 4.18 Diabetic medication class and glycaemic control 
Medication Class Combination % controlled % uncontrolled 
metformin only 38.89 61.11 
sulphonylurea only 50.00 50.00 
metformin and sulphonylurea 27.78 72.22 
insulin only 44.44 55.56 
insulin and metformin 10.34 89.66 
insulin and sulphonylurea 20.00 80.00 
all three 7.41 92.59 
                                  Pearson χ2 = 14.0593,   p = 0.029 
Both analyses showed a statistically significant association with glycaemic control.  However, the 
association with medication class is not valid since a number of cells in  the χ
2
  cross-tabulation had an 
expected value < 5. 
4.9.4  Demographics 
 Race and Residence were the only demographic variables that showed association with glycaemic 
control.  The proportion of control amongst Whites was more than double that amongst Blacks.   There 
was only one Indian in the sample which precludes any conclusion about control in this group.  Also, the 
association with race, although statistically significant, was not valid. This was probably due to there 
being only one individual of a racial group other than Black or White.  After race was re-coded as a 
binary variable with 2 categories, “Black” and “Other”, the association was both valid and significant 
Participants living in the catchment area had a higher proportion of control than those living outside.  
These findings are depicted in tables 4.19, 4.20 and 4.21 below. 
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Table 4.19 Glycaemic control amongst the 3 racial groups 
Race % controlled % uncontrolled 
Black 21.3 78.70 
White 45.45 54.55 
Indian 100 0 
             Pearson χ
2
 = 9.2438, p = 0.01 
Table 4.20 Dichotomous association of race and glycaemic control 
Race % controlled  % uncontrolled  
Black 21.3 78.7 
Other 47.83 52.17 
             Pearson χ
2
 = 7.5986, p = 0.006 
 
Table 4.21 Glycaemic control according to residence in the catchment area 
Residence % controlled  % uncontrolled 
catchment 37.25 62.75 
outside catchment 19.86 80.14 
                                            Pearson χ
2
 = 6.1314, p = 0.013 
4.9.5  Clinical parameters 
Amongst the clinical parameters, only co-morbidity was associated with glycaemic control. Specifically, 
the presence of CCF, irrespective of the presence of any other co-morbidity, conferred a higher 
proportion of   control. The presence of any co-morbidity in general and, hypertension in particular, did 
not influence control. 
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Table 4.22 The presence of any co-morbid condition and glycaemic control 
Any Co-Morbid Condition % controlled % uncontrolled 
present 25.29 74.71 
absent 14.29 85.71 
                                      Pearson χ
2
 = 0.8484,   p = 0.523 (Fisher’s exact) 
Table 4.23 The  presence of hypertension and glycaemic control 
Hypertension % controlled % uncontrolled 
present 24.85 75.15 
absent 20.00 80.00 
      Pearson χ
2
 = 0.1756,   p = 1.00 (Fisher’s exact) 
Table 4.24 The  presence of CCF and glycaemic control 
CCF % controlled % uncontrolled 
present 44.44 55.56 
absent 22.29 77.71 
                                        Pearson χ
2
 = 4.3145, p = 0.047 (Fisher’s exact) 
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4.9.6 Summary of variables  associated  with glycaemic control on univariate analysis 
Variables that showed a statistically significant association with glycaemic control are summarized in 
table 4.25 below.  Also included were variables whose associations were statistically significant but not 
valid.   
Table 4.25 Univariate associations with glycaemic control 
Variable p-value 
Race* 0.006 
Residence 0.013 
Combinations  of 
Treatment Type 
0.003 
Combinations of 
Medication Class 
0.029** 
Presence of CCF 0.047 
*Dichotomous classification 
**statistically significant but not valid 
In summary, on univariate analyses, race, residence in the catchment area, the presence of CCF and, 
drug class, types and combinations thereof, all appear to influence glycaemic control in this study. 
Processes of care and the reported receipt of lifestyle advice demonstrate no such association.  
 
4.10  Logistic models of glycaemic control 
4.10.1  The unadjusted model 
As an initial step to developing a multivariate logistic model , each  variable found to have a statistically 
significant association  with glycaemic control  on prior univariate analysis  was tested individually  to 
determine unadjusted odds ratios ( OR’s).  These are depicted in table 4.26.  Statistically significant OR’s 
and their associated p-values are shown in bold. 
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Table 4.26 Unadjusted odds ratios for variables associated with glycaemic control 
Variable Categories Unadjusted 
OR’s 
p-value 
race Black 
Other 
1 
3.387 
 
0.008 
residence Outside catchment 
Catchment 
1 
2.396206 
 
0.015 
treatment type combinations Insulin only 
Oral and insulin 
Oral only 
1 
0.1363636 
0.5537975 
 
0.012 
0.399 
medication class combinations Insulin only 
Insulin and metformin 
All three 
Metformin only 
Sulphonylurea only 
Metformin and sulphonylurea 
Insulin and sulphonylurea 
 
1 
0.1442308 
0.1 
0.7954545 
1.25 
0.4807692 
0.3125 
 
0.033 
0.021 
0.782 
0.833 
0.303 
0.372 
CCF CCF absent 
CCF present 
1 
2.789189 
 
0.044 
 
For  treatment type, compared to insulin only, lower odds of control was  associated with  being on a 
combination of oral and insulin medication.  A similar pattern was noted for   medication class: 
compared to insulin monotherapy, lower odds of control was associated with being on a combination of 
insulin and metformin,  or being on  a combination of all 3 medication classes.  The odds of control 
associated with the other medication combinations were not statistically different from that associated 
with insulin monotherapy.   
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4.10.2  Multivariate logistic models for glycaemic  control 
To develop a parsimonious multivariate logistic model for glycaemic control, all the variables in the 
previous section were simultaneously tested for association using logistic regression.   Due to the 
collinearity between the treatment type and medication class variables, 2 logistic models were derived: 
one with treatment type and the other with medication class.   These models are detailed in the 
following tables: 
Table 4.27 Multivariate logistic model  for glycaemic control: Model 1 
Variable Categories Adjusted OR’s p-value 
treatment type Insulin only 
Insulin and oral 
1 
0.2154445 
reference 
0.001 
CCF Absent 
Present 
1 
3.374822 
 
0.026 
 
Table 4.28 Multivariate logistic model  for glycaemic control: Model 2 
Variable Categories Adjusted OR p-value 
medication  class Insulin only 
Insulin and metformin 
All three 
1 
0.2161132 
0.1858542 
reference 
0.020 
0.027 
CCF Absent 
Present 
1 
3.172564 
 
0.035 
 
Collinearity was also evident between race and residence but this was of no consequence since both 
were eliminated from either model.   The association patterns for the remaining variables reflect those 
found on univariate analyses: pharmacological treatment and the presence of a co-morbidity, CCF, were 
the only factors demonstrated to be independently associated with glycaemic control in this study.   
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Compared to insulin only, combined treatment with insulin and an oral medication was associated  with 
an almost four-fold lower odds for control. Combination treatment with insulin and metformin, as well 
as treatment with the combination of all three classes of medications, were associated with similarly low 
odds for control compared to treatment with insulin monotherapy.  Individuals with CCF were three 
times more likely to have better control than those without CCF. 
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CHAPTER 5 
DISCUSSION 
_____________________________________________________________________________________ 
5.1  Introduction 
This chapter is presented in two parts.   The first part deals with the descriptive aspects of this study and 
comprises sections 5.1 to 5.5, while in the second part, section 5.6, analytic aspects are considered.  In 
either case, discussion is primarily focused on the components relating the aim of this study viz., 
processes of care, lifestyle advice, treatment and glycaemic control.  Additionally, in the analytic section, 
other variables found to have statistically significant associations with glycaemic control in both the un-
adjusted, as well as adjusted models, are also discussed.  Comparisons are made with results in other 
research and, where possible, explanations for findings in the present study are advanced. 
5.2  Demographics 
5.2.1  Age and sex 
Mean age of subjects in this study was 58 years and the majority were aged 50 years or more.  These 
figures are consistent with those in most other studies.
3,15,29,103,104
  According to  IDF estimates for South 
Africa in 2010, individuals in the 40-79 age group accounted for 82.2% of adult diabetics in the country.
2
  
This finding is reflected in the present study where the age group 50-79 years comprised 82% of the 
sample. 
Females constituted the majority, 63%, of the sample in the present study. This differs from  some  local 
studies in primary care  settings.  In the Moodly and Rambiritch study, almost 70% of the sample were 
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female
14
; a similar proportion of females occurred in the study by Steyn et al., which looked at both 
diabetics and hypertensives.
15
  
In contrast, the sex distribution in the present study is consistent with country-wide epidemiological 
estimates and, moreover, while actual estimates differ,  echo  the overall trend of female 
preponderance.
2,3
  According to Bradshaw et al., prevalence of the disease amongst females over 30 
years in 2000 was 6.2% as compared to 4.7% in males.
3
   More recent estimates by the IDF show a 
preservation of this trend: for 2010, the IDF estimated females to constitute almost 61% of all adult 
diabetics in South Africa
2
; furthermore, the IDF predicts that this proportion will remain unchanged for 
2030. 
   Elsewhere sex distribution in studies on adult diabetics display varying trends.  According to Saadine et 
al
29
, in their analysis of data from the Behavioural Risk Factor Surveillance System (BRFSS) for 2002, 
females made up 51% of the sample.  Data from the National Health and Nutritional Examination Survey 
(NHANES) for 1999-2002 in the same study showed the opposite:  47% were females. In the UKPDS 
(UKPDS 35)
105
, females only made up 30% of the sample.  Other studies however show a clear pattern of 
females outnumbering males.
103,104
 
5.2.2  Race and residence 
By  racial  groups in South Africa, prevalence appears to be highest amongst the Indian population with  
estimates varying from 10 to 17%.3,25  Estimates in the Black population vary from 4.8% to 8%25,3, while 
that for the Whites is 6.2%.3  
In the present study, Blacks constituted 87.5% of the sample and this figure does not appear to conform  
with accepted estimates for race specific prevalence of the disease in this country.  
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However, since this study did not measure actual prevalence, any number of other factors could have 
influenced this finding.   
A likely explanation is the observed association between race and residence: surrounding   
Vanderbijlpark, the catchment area of the study facility, are a number of townships whose populations 
are overwhelmingly Black and, individuals from these areas constituted three-quarters of the present 
study sample. 
 
5.2.3  Education and employment status 
Most individuals in this study, 87%, had some form of education while only 5.5% had achieved either 
matriculation or some form of tertiary education.  In most of the local studies that were consulted, 
education levels of their samples were not explicitly described.  One local study found that almost half 
of their sample had either primary school or no education at all.
15
  This is comparable to that in the 
present study where 46.8% were noted to have either primary school or no education 
 Comparison with international studies is problematic on account of differing standards and 
classifications of educational achievement.  However, some differences are possible to glean. For 
example, in the NHANES and BRFSS analyses by Saddine et al., at least 66% had at least a high school 
education.
29
  On the other hand, in a study by Rothman et al., whose sample had a wide socio-economic 
spectrum, almost 57% had less than a high school education.
106
  
Almost 41% of participants reported being unemployed and this reflects the overall unemployment rate 
in Sedibeng district which, at the time of this study, was estimated to be between 35 and 40%.
107
   Of 
those that receive some form of income either through formal employment or a state pension, the 
latter accounted for 30% of the total sample. What this implies is that, given the fact that a state 
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pension cannot adequately meet all of the needs of the beneficiary, more than 70% of individuals in this 
study have either an inadequate, or no income.  These patterns are reflected in other South African 
studies in similar settings.
15,16
 
Not only is lower socio-economic status associated with a higher prevalence of type 2 diabetes
108
, low 
income earners and individuals with low literacy levels suffer greater morbidity as a result of the 
disease.
109
  In particular, low socio-economic status amongst type 2 diabetics is associated with greater 
levels of obesity, LDL cholesterol levels and poor glycaemic control.
108
  This observation has obvious 
relevance in the present study where the majority of participants were found to have an inadequate 
income.  
 Health literacy, which is influenced by education status
110
, has been shown to impact diabetes 
knowledge and self-care practices.
111
 However,  the presence of education , while necessary, might not 
in itself be sufficient-the level of education is also important: Schiller et al., demonstrated that 
individuals with either some or less than, high school education  had inadequate levels of health 
literacy.
110
   In the present study, while nearly 90% had some form of education, less than 6% were 
noted to posses either matric or some form of tertiary education.  What this demonstrates is that the 
vast majority of the study sample possibly lacks a sufficient level of literacy required to positively 
influence   vital diabetic self-care practices. 
 
5.3  Glycaemic control 
Local and international guidelines for glycaemic control in type 2 diabetes recommend an HbA1c level of 
less than 7% as ideal.
10,11
 There is however no clear consensus on classification of control for HbA1c 
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above this target value.  Nagpal and Bhartia define “poor control” as an HbA1c greater than 8% 
32
, while 
Maizlish et al
31
 and Saaddine et al
29
 use an HbA1c > 9% as their definition of poor control. 
 Oster et al., on the other hand, define as “inadequate”, HbA1c levels above 8.4%. 
40
   Still other 
researchers use the term “controlled glycaemia” for HbA1c below 8%.
35
 
In the present study, the mean HbA1c was 8.55%.  The lower limit of the 95% CI for the mean HbA1c 
demonstrates clear statistical evidence for overall poor control which is confirmed by the finding that 
less than a quarter of the sample had controlled glycaemia.    Using the ACCORD criteria 102, 20% percent 
were classified as having achieved the standard glycaemic target while the majority, 55%, were classified 
as poorly controlled. 
The trend of low proportions of individuals with type 2 diabetes mellitus achieving optimal target HbA1c 
levels is reflected in local and international studies. Moreover, this trend appears to be preserved across 
differing socio-economic strata.32,25,40  In a survey of glyceamic control trends in the USA using NHANES 
data, Koro et al., demonstrated that the proportion of adults with type 2 diabetes achieving optimal 
control declined from 44.5% to 35,8% between the years 1988 to 2000.112  In the study by Bhartia and 
Nagpal which looked at diabetes care amongst a sample of middle and high income group individuals in 
Delhi, 37.8% of the sample had optimal glycated haemoglobin levels.
32
   A diabetes care survey amongst 
First Nation communities in Alberta showed that only 30% achieved optimal HbA1c levels.
40
  In a 
baseline survey,  carried out as part of an intervention study to improve diabetes processes of care and 
outcomes  amongst  two Aboriginal communities in Australia by Baillie et al.,  19 % of the study sample 
had optimal HbA1c levels.
35
 
In South Africa, the paucity of large scale studies obviate the  availability of  reliable figures on glycaemic 
control but existing data from primary care as well as hospital settings  point  to a pattern of  low  
proportion of glycaemic  control.    
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While some studies demonstrate levels of control comparable to the present study, others  display  a 
more pessimistic picture.  Govender and Klop, in their post-intervention study at a rural hospital in KZN, 
achieved  optimal HbA1c levels in 10%  of their sample.
12
  
 A survey carried out a an OPD of a large Tshwane hospital by Westaway et al., showed optimal HbA1c in 
just one-third of the study sample.
113
  In a study of diabetes care amongst a population in a rural 
KwaZulu-Natal district served by primary care facilities, Rotchford and Rotchford found that just under 
16% of their sample had an HbA1c of less than 7.7%.
16
   While the sample in this study consisted of both 
type 1 and type 2 diabetic patients, the former comprised only 7.1% of the total sample.  The proportion 
of optimal glycaemic control in the present study reflects similar results from the larger survey carried 
out by Steyn et al., in a number of primary care facilities in the Cape Peninsula; there, 24% had optimal 
glycaemic control.
15
 
Quite independently of other risk factors, the presence of diabetes has been demonstrated to confer 
twice the excess risk for a wide range of cardiovascular diseases (CVD) as compared to individuals 
without diabetes.
114
   Seminal studies such as the DCCT
28
 and the UKPDS
7,8
, have clearly demonstrated 
the benefits of proper glycaemic control.  In the latter study, these benefits were shown to accrue 
largely due to reductions in microvascular complications.
7
  Moreover, not only  do  these benefits  
persist,  long term treatment  has subsequently  been shown to  also  reduce macrovsacular risk
8
,  a 
finding not demonstrated in the original UKPDS.
7
  
While these landmark studies clearly established the benefits of glycaemic control, the question of  a 
possible relation between the degree of glycaemia and risk of complications  over time in Type 2 
diabetics had not been adequately addressed.  The risk of micro- and macrovascular complications at 
different levels of glycaemia was investigated in a sub-study of the original UKPDS.
105
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Based on the participants of UKPDS 33, this study, UKPDS 35, revealed a clear correlation between levels 
of glycaemia   and the incidence of complications.   
Specifically, for every 1% drop in mean HbA1c, the following risk reductions were demonstrated: 
• 21%   in any endpoint related to diabetes 
• 37%  for microvascular endpoints 
• 43%  for  amputation  or death from peripheral vascular disease 
• 14%  for myocardial infarction 
• 16% for heart failure 
• 12% for stroke 
This finding is of particular relevance to the target population of the present study: while the latter 
clearly highlights the huge strides that are still required to achieve adequate glycaemic control, the 
above results point to the potential benefit of reducing mean HbA1c by one percentage point. One 
implication of this is that a shift from looking only at the proportion of individuals with optimal control, 
to focusing on incremental reductions in HbA1c levels without necessarily achieving optimal glycaemia,  
is  a plausible first step in reducing morbidity and mortality especially in resource constrained settings 
such as the one in which the present study was conducted.  
 
5.4  Processes of care 
The majority of patients, 93%, had their blood pressure recorded at every visit.   Proportions for 
frequency of performance in the remaining processes of care ranged from 0 to 2%.  Only 1.6% of the 
sample met the criteria for frequency of HbA1c and BMI determinations while none of the sample met 
the criteria for frequency for weight or WC monitoring.   
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Selection of process of care indicators  for management of type 2 diabetes vary between local and 
international guidelines
10,11,33
, a phenomenon  reflected in studies looking at processes of care in various 
settings. However, amongst the large variety indicators, HbA1c determination is ubiquitously 
recommended as a core process of care measure
10,11,33
  and there are 2 reasons for this: 
• HbA1c reflects the average blood glucose over at least the preceding 6 weeks5 
• HbA1c levels are correlated with micro- and macro-vascular complications105 
Findings for frequency of HbA1c determinations in most international studies vary according to country 
and setting.   Results from a diabetes care survey in 5 OECD countries (Australia, New Zealand, UK, 
Canada and USA) by Damin et al., revealed  high rates of annual HbA1c determinations.
115
   The lowest 
countrywide overall rate of testing (65%) was found in Australia.  There was however considerable sub-
group variation: in New Zealand for instance, testing rates amongst Maoris was noted to be 39% whilst 
that amongst individuals of Pacific Island origin was 99%.  In the study of diabetes care amongst First 
Nation individuals in  Alberta, Canada with type 2 DM by  Oster et al., 46% had an HbA1c done within 
the preceding 6 months while a further 20% had one within the preceding 6-12 months.40   Similarly, in 
an intervention study to improve trends in processes of care amongst an Aboriginal population in 
Australia, Bailie et al., found that, at baseline,  53% of their sample met the criteria for frequency of 
HbA1c testing.
35
  In the USA, findings of a study amongst Latinos with diabetes in managed care revealed 
over 80% of subjects had an HbA1c level done in the preceding 12 months.
116
   A similar high proportion 
was noted in the Maizlish study.
31
   
Alberti et al, who conducted a large study looking at quality of care issues amongst mainly Type 2 
diabetics from low to mid-income groups at 48 primary care facilities in Tunisia, found that only 5% of 
patients in their sample had at least one HbA1c determination in the previous year.104 
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What this clearly  demonstrates, is that  the  proportion of patients meeting the accepted criteria for 
frequency of HbA1c assessment in the present study falls markedly below  levels achieved in similar 
settings in other, mainly western, countries and  reflects  a slightly better proportion  of monitoring than 
that  shown in  one other local study in  a primary care setting:   Steyn et al., found that  only 2.6% of 
subjects had an HbA1c recorded in the last 12 months.
15
  It is well established that diabetic 
complications are related to glycaemic levels as measured by HbA1 and, more importantly, that 
reductions in HbA1c of 1% can achieve significant risk reductions for any diabetes related endpoint.
105
  
Consequently, in the effort to realize such benefits, proper monitoring assumes a critical role in alerting 
clinicians  to the need for reducing HbA1c. In this regard, the low level of HbA1c monitoring 
demonstrated in the present study represents a significant shortcoming in the overall management of 
diabetes and, in particular, the prevention of diabetes related complications. 
Over three-quarters of the available patient records for the sample in the present study was noted to 
have a routine finger-prick blood glucose determination recorded  at every diabetic visit and , while this 
high proportion seems encouraging,  its merits are questionable  given that  neither the ADA nor the  
SEMDSA  guidelines appear to recommend routine office determinations of  blood glucose levels. 
10,11
    
A partial explanation for its exclusion as a core process of care measure is provided by van Zyl who 
argues that, while both fasting and random blood glucose levels can give an indication of glycaemic 
control, patients sometimes change their behavior prior to follow up visits: “They tend to skip meals or 
inject more insulin a few days before they visit..” 
117
   This notwithstanding,   the use of finger-prick 
glucose determinations cannot be entirely discounted.  Of particular importance is its obvious utility in 
the detection of individuals presenting with asymptomatic hypo- or hyperglycaemia during routine 
diabetic visits.  Additionally, there is evidence to suggest the existence of a moderate association 
between FPG and CHD.
114
   The routine use of FPG is however limited by the inconvenience of having to 
fast  prior  to  measurement.  
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Comparisons for attainment of process of care measures for BP monitoring with other studies are 
hampered by the application of differing standards.  In some studies, authors required that BP be 
measured at least once a year
45,118
, while in others, no specific standard was made explicit.
15,16
  
Nevertheless, in studies that applied the accepted standard of requiring BP measurements at every 
follow-up visit , levels of attainment approached 80% 
119,120 
;  in the Alberti study, 92% of the sample met 
the standard for BP monitoring.
104
  
The finding in the present study that levels of BP monitoring are not only comparable to, but exceeded 
that found in other studies referenced, is important.   Not only is hypertension one of the two 
commonest co-morbidities found in type 2 DM
11,121 
,  it is also an important risk factor for CVD and 
micro-vascular complications.
11
 For these reasons, the detection and control of this condition forms a 
cornerstone in prevention of mortality and morbidity in   patients with type 2 DM.
10,11
 
Weight control is a key component in the overall management of type 2 diabetes and clear 
recommendations exist  for  BMI and WC targets.
10,11
   Necessarily then, screening and monitoring of 
these parameters becomes an important process of care activity.  Current South African guidelines 
suggest that weight and WC be measured at each visit, while BMI only be determined yearly.
10
   Studies 
where either weight or BMI monitoring was assessed, revealed achievement of recommended standards 
to exceed 50%.
45,104
  In the study by Bailie et al., attainment of monitoring at baseline for BMI 
approached 30%  despite the requirement that this parameter be measured twice a year.
35
 
It had been previously supposed that within a given BMI category, risk for obesity-related co-morbidity 
was related to WC
122 
; this possibly explains why, both in the present study as well as in the majority of 
studies referenced, with the exception of that by  Bailie et al
35
,  WC monitoring does not appear to be a 
routine process of care measure.  Subsequent research by Janssen and co-workers has, however, called 
into question this previously held relationship between BMI and WC.
123
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 According to the researchers, “the primary finding of this study, that BMI coupled with WC did not 
predict obesity-related health risk better than did WC alone when these 2 anthropometric measures 
were examined on a continuous scale, indicates that WC, and not BMI, explains obesity-related health 
risk” and add that   “when WC is dichotomized as a normal or high-risk value according to the NIH 
obesity guidelines, BMI remains a significant predictor of metabolic health risk.”   
 These findings suggest that WC, instead of BMI, should be the primary parameter for assessing obesity 
related risk; moreover WC measurement is easy to perform, is not time-consuming and requires no 
specialized equipment 
 Whether considered in isolation or in comparison with other studies,   the significantly low rates of 
achievement of accepted standards for processes of care measured in this study, highlights a serious 
problem in the monitoring of quality and the identification of gaps in the delivery of diabetic care.  While 
the exact reasons for this are not immediately clear, a number of explanations might be postulated.  
One possibility is the lack of clinician awareness or understanding of the importance of routinely 
assessing these parameters in accordance with accepted guidelines.
124
   Other, often cited, barriers are 
lack of resources and consultation time pressure in busy primary care settings.
125,126
  Barnes et al., 
conducted a study documenting consultation times amongst patients attended to by general internal 
medicine residents at a busy general medical clinic and found that clinicians spent an average of 5 
minutes on diabetic patient consultations.
127
 This latter finding is particularly relevant in the present 
study where, at the time of data collection, the study facility served a catchment population of over 70 
000 people with 2 full-time  and 2  part-time  medical officers . 
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5.5  Lifestyle advice on diet, exercise and weight control 
 Twenty-two percent of participants reported not receiving any information on the 3 lifestyle 
management components of weight loss, diet and exercise.  Advice on exercise and weight control was 
reported by 68% of the sample while nearly 79% reported receipt of advice on diet.  Very few individuals 
received advice on only one or two of the components; the vast majority (80%) reported receipt of 
information on all 3 components.  These findings differ markedly with those in the South African study 
by Moodley and Rambiritch.
14
  One component of their investigation looked at, inter alia, receipt of 
counseling on diet and exercise.  Their results showed that 32% were counseled on  diet and exercise, 
and 29% received counseling on exercise only; no figure was reported on diet counseling alone.   
The relatively high rates of reported advice in the present study are similar to those found in large 
surveys elsewhere:  In the Galuska study
70
, nearly two-thirds of obese diabetics were advised to lose 
weight while 73% of diabetics in the Morrato study
75
 were told by a health professional to exercise 
more. One shortcoming in these comparisons is that both  studies considered only a single component 
of the lifestyle parameters investigated in the present study.  A more direct comparison can be made 
with the Jorgensen study
76
, which looked at all 3 parameters.  Here, frequency of advice on weight 
reduction and diet management both exceeded that found in the present study  while  the reverse was 
true for receipt of  exercise advice. 
Overweight and obesity in diabetes significantly increase the risk of CVD and other co-morbidities 
128  
due to worsening insulin resistance, dyslipidaemia, blood pressure and vascular endothelial 
dysfunction.
129
   For this reason, weight control is a key therapeutic objective.
53,130 
  Exercise and diet are 
the main ways of achieving and maintaining weight  control
130
,  and, the provision of advice in  this 
regard is recognized as an important component of lifestyle management.10,11,130   In light of this, and the 
fact that the majority of the sample were obese, the high level of reported receipt of weight loss, 
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exercise and diet advice in the present study is noteworthy.  Caution  should, however, be exercised in 
regarding this as a genuinely positive finding since information for this was self-reported and prone to 
both recall as well as reporting bias.   
 
5.6  Diabetic medication 
It was noted in Section 4.0 that complete information on medicines prescribed was only available for 
191 individuals and all of these were on some form of drug treatment.  Even considering a worst-case 
scenario where it is assumed that the other 9 patients were on no diabetic medication, we can still 
conclude that at least 95% of the original  sample of 200 were on drug treatment. 
Oral medications alone were prescribed in 63%, insulin was prescribed alone in 5%,  and 32% were on a 
combination of both.  Comparison with other local studies reveal higher insulin use but comparable or 
lower oral medication use.  In the Steyn study
15
, nearly 10% of the sample was on insulin while 68% 
were on oral medications; 18% of the cohort in the hospital based study by Van Zyl and Rheeder was on 
insulin, 53% on oral drugs and 28% on a combination of both.
13
 
Data from elsewhere reveals similar
35
 or lower
131
 proportions of insulin use compared to the present 
study. The reverse trend was noted for oral medication use with generally higher use of oral  agents 
elsewhere.
35, 104
 
 Ninety-five percent of the patient sample in the present study who were on oral treatment only (n= 
120), either as mono- or  combination  therapy,  had been prescribed  metformin, while nearly 80% 
were on two drugs; only 5% were on sulphonylurea  monotherapy.  While these findings appear to 
contradict trends elsewhere
131,132 
, they are consistent with that found in at least one local study
133 
and 
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possibly reflect suggestions  in current South African  guidelines that  recommend metformin,  in the 
absence of contra-indications, as first line oral treatment.
10
  
Insulin therapy, either alone or in combination with oral agents, was prescribed in 71 (37%) individuals 
in the present study.  Of these, the majority were on combined insulin and metformin (42%) or on triple 
therapy (38%).  A minority were either on insulin only (13%) or on a combination of insulin and a 
suphonylurea (7%).  Comparison with other data was hampered by the fact that most of the studies 
referenced did not describe a breakdown of specific oral drug classes but mainly described prescription 
patterns in terms of oral or insulin use. 
The second most frequent drug combination in the present study was that of insulin and metformin. 
This combination holds a number of advantages.  One is the potential of metformin to counteract the 
weight gain due to insulin; another is the lower incidence of hypoglycaemic episodes. 
95
  Additionally, 
meformin can improve lipid profiles and improve macrovascular risk.
84,96
   
 It is noteworthy in the present study that 17% of patients were on a combination of insulin and a 
suphonylurea, with or without metformin.  Current opinion on the combination of insulin and 
sulphonylureas  appear equivocal: SEMDSA recommends that sulphonylureas  be continued if basal 
insulin is initiated but should be stopped in the case of biphasic insulin
10
 ; other experts appear to 
advocate continuation of sulphonylureas irrespective of insulin regime.
20,117
  The combination of 
sulphnylureas with insulin is controversial for two main reasons: first, both sulphonylureas and insulin 
promote weight gain20,117 and second, sulphonylureas may adversely affect β-cell function with 
progressive use.
88,92
  As noted elsewhere in this report, both of these have negative repercussions on 
metabolic control in type 2 DM and the relatively high proportion of individuals on this combination, 
with or without metformin, is of concern.  However, there may be some benefit in combining all three 
drug classes: the insulin sparing effect appears to be highest with the triple combination.
95,96
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A small proportion of the sample, 8%, in the present study was on insulin monotherapy.  While this at 
first might seem  counter to current recommendations that advise  retaining oral treatment, especially  
metformin,  after augmentation with insulin,  there is  evidence in the literature suggesting the viability 
of using insulin as monotherapy in Type 2 diabetes.
92
   Some caution should be exercised in the 
interpretation of such evidence : while suphonylureas  appear to compromise β-cell function, metformin 
has a number of  beneficial metabolic effects, not least of which is  the added potential of counter-
balancing insulin induced weight gain
7,95,96
  and its continued use with insulin is recommended in local 
and international guidelines.
10,11,134
    However, insulin mono-therapy has the practical advantage of 
reducing poly-pharmacy and could be considered in individualized cases. 
 
5.7 Associations of glycaemic control 
5.7.1   Processes of care 
With the exception of monthly BP monitoring, which was demonstrated to have no influence on 
glycaemic control, the proportions for the other processes of care that met the standard for 
performance  were  too small to test for association with glycaemic control in the present study.   
Since the influence of process of care  in respect of HbA1c, BMI and WC  monitoring  on glycaemic 
control could not be determined in this study, direct comparisons with other studies  becomes difficult.  
Comparisons with other South African research are further hampered by the fact that, with the 
exception of the study by Van Zyl and Rheeder
13
, none of the South African studies explicitly stated the 
applicable standard for process of  care  assessments. 
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 Research elsewhere however, reflects a pattern of non-concordance of processes of care indicators 
with glycaemic control.  Pederson conducted a cross-sectional study to assess the management of type 
2 diabetics in Greenland attending primary health clinics and found no association between processes of 
care and HbA1c levels.
118
 In a comparison of diabetes management in 5 countries, Damin et al., 
demonstrated better glycaemic control in countries that measured worse for levels of processes of 
care.
115
  
While these findings suggest that generally, there is  no association between process of care measures 
and glycaemic control, it might be reasonable to speculate as to whether there might exist specific 
conditions in the present study that could possibly have influenced the null association. Two such 
factors bear further scrutiny. First is the limited number of processes  investigated. Second is the fact 
that diabetic care is rendered by non-specialist clinicians. Evidence suggests that both these might play 
no role.  In the TRIAD study, researchers sought to determine whether variations in the number of 
process of care was associated with, inter alia, HbA1c and found that the addition of one more 
documented process of care had no influence on glycaemic control.
43
  De Bererdis et al., compared 
quality and outcomes of care amongst type 2 diabetic patients attending either diabetic outpatient 
clinics or general practitioners and found that while attainment for process of care measures was better 
in the former,   metabolic control showed no statistical difference.
42
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5.7.2   Diet, exercise and weight control advice received 
No statistically significant association between self-reported receipt of counseling on any one of diet, 
exercise or weight loss and glycaemic control was demonstrated in this study although there appeared 
to be a trend of greater proportion of controlled glycaemia amongst those reporting no advice.   
Similarly, receipt of any advice compared with no advice showed no association with glycaemic control 
but again the trend of higher proportion of control amongst those reporting no advice received was 
preserved.   
 These results confirm some findings some studies while differing from others.  In a similar cross-
sectional sectional study by Blaum et al., absence of dietary advice was independently associated with 
poor glycaemic control.
135
  It should be noted that the authors characterized HbA1c > 11% as poorly 
controlled glycaemia.  Two follow-up studies, one of which included a nutritional education component 
in its self-management education intervention136 while in the other diet, exercise and weight 
management advice were all given137, showed no post-intervention impact on glycaemic control.  A 
recent systematic review found that while exercise advice alone had no impact on glycaemic control, 
improvements in HbA1c were realized when exercise advice was combined with  nutritional   advice.138  
Although no association between receipt of lifestyle advice and glycaemic control could be 
demonstrated in the present study, it should be noted that the nature, content and frequency of such 
advice was not ascertained and neither was the category of HCW delivering this advice identified.  This is 
important since other studies have shown that specialized forms of lifestyle counseling in certain 
contexts do in fact yield beneficial effects on glycaemic control.
59,80
   Also, as pointed out elsewhere in 
this chapter, since information for this aspect of the present study was self-reported, the role of bias 
cannot be excluded.  
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 In the final analysis, the potential of any beneficial effect of lifestyle advice upon glycaemic control can 
only be realized upon translation into practice, an effect not investigated in the present study.  
However, some idea of the degree of this translation might be gleaned from the observation that the 
majority of participants in this study had an unsatisfactory anthropomorphic profile.  
 
5.7.3  Diabetic medication 
Types of treatment and combinations thereof had a significant influence on glycaemic control.  In 
particular, patients on a combination of oral and insulin treatment had the lowest proportion of control.   
This finding was further elaborated after sub-division into actual medication classes and combinations 
thereof. Here, the lowest proportion of control occurred in patients on a combination of all 3 treatment 
classes as well as in those on a combination of insulin and metformin.   Statistical confirmation of this 
was demonstrated on univariate and multivariate  logistic regression where odds of lower proportions 
of controlled glycaemia  were significantly associated with both these combinations.   
The highest proportions of control occurred in patients on mono-therapy:  50%, 44% and 39% in the 
suphonylurea, insulin and metformin groups respectively.  These findings appear similar to results in the 
sulphonylurea, insulin and metformin treatment arms of the UKPDS 49 study where 50%, 47%  and 44% 
of subjects respectively,  achieved control after 3 years of treatment initiation.
82
  
With the exception of the insulin and sulphonylyurea combination, the finding in the present study of 
lower odds of glycaemic control for all other combinations involving insulin as compared to insulin alone 
is not supported by literature.  There is clear evidence, for example, that the insulin plus metformin 
combination achieves glycaemic control comparable to, or better than, insulin alone. 
94,96,139
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Similarly, compelling evidence from at least one controlled trial suggests that the addition of any insulin 
regime to a baseline combination therapy of metformin and sulphonylurea results in significantly better 
glycaemic control.
140
 
A  number of factors might be postulated to explain these discordant findings .     Clinical inertia and the 
delayed recognition of secondary failure are  possibilities.  Clinical inertia may be described as the failure 
to intensify treatment in the face of inadequate control.
141
   Shah et al., who studied this phenomenon 
amongst specialist and generalist physicians attending to a large cohort of elderly diabetics on oral drugs 
in Ontario noted that treatment intensification in response to inadequate glycaemic control occurred in 
45% of patients attending specialists ; the corresponding figure for generalists was 37.4%.
142
  In the 
primary care context,  Calvert et al., looking at the management of diabetics on oral therapy attending 
general practitioners found that “oral treatment was not started until glycaemic control is poor” and 
patients remained on monotherapy for a median of almost 4 years before addition of a second oral 
agent.
132
   In the present study, the cohort on combination insulin and oral therapy had a median 
disease duration of 7 years and were on insulin for a median of 16 months (Appendix G, table G.1) which 
suggests that this group had insulin added nearly six years after initial diagnosis.   These figures point to 
a possible delay in the recognition of the secondary failure phenomenon of oral drugs and the 
consequential failure in the timeous initiation of insulin.  One factor contributing to this delay is the 
significantly inadequate level of HbA1c monitoring noted in this study.  Additionally, clinicians might 
delay initiation and/or intensification of insulin to avoid weight gain, risks of hypoglycaemia or 
polypharmacy.
83
 The  influence of polypharmacy and weight gain is particularly relevant in the present 
study where obesity and the presence of at least one documented co-morbidity was noted in the vast 
majority of the cohort.  Finally, the possible role of patient-provider interaction might also be 
mentioned: on the one hand, patients and providers often differ in treatment priorities
143
 while on the 
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other, patients and clinicians often “collude in implicit and unspoken contracts to continue oral agents 
for as long as possible.” 
83
 
A small proportion of the  sample, 8%, in the present study was on insulin monotherapy , and both this  
as well as  the  suphonylurea only group,  had  highest proportions of  glycaemic control.   While this at 
first might seem counter-intuitive, there is evidence in the literature regarding the viability of using 
insulin as monotherapy in Type 2 diabetes.  
 In a comprehensive review on the question, Massi-Benedetti and Orsini-Federici make a compelling 
case for the use of insulin monotherapy after failure of oral treatment.
92
   They cite the following  well 
founded evidence to support their case: 
• Insulin preserves β-cell function whereas sulphonylureas have been shown to be detrimental 
• Insulin provides better glycaemic control 
• Monotherapy reduces poly-pharmacy  
Some caution should be exercised in the interpretation of these findings.  It does not necessarily follow 
that insulin monotherapy is better than any combination of insulin and an oral agent: while 
suphonylureas  appear to compromise β-cell function, metformin , despite the possibility of secondary 
failure, has other beneficial metabolic effects
7,96
 and its continued use with insulin is recommended in 
local and international guidelines.
10,11,134
   These guidelines, however, also recommend the continued 
use of sulphonylureas with insulin. 
While patterns of glycaemic control associated with drug classes and combinations thereof in  the  
present study appear to differ from results elsewhere, the overall finding that treatment, after 
controlling for other factors ,  emerged as an independent co-variate of control is borne out by at least 
one  systematic review that investigated the relation between quality of care indicators and diabetic 
outcomes.
144
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Reporting on their findings, the authors of this study concluded that: “Process indicators focusing on 
intensification of drug treatment were significantly associated with better surrogate outcomes…” 
144
 
5.7.4  Co-morbid medical conditions 
Figures reported in the literature demonstrate that most diabetics have at least one co-morbid 
condition143,145  and  that 40% of diabetics  have three or more.145   The former observation is borne out 
by the  present study where over 90% of the sample were found to have at least one such condition; 
however only 18% had more than one documented co-morbidity and none of the patient records 
reflected more than two. 
One useful categorization of co-morbidities has been suggested by Piette and Kerr who distinguish 
between “concordant” and “discordant” co-morbidities: concordant conditions are those that 
“represent parts of the same overall pathophysiological risk profile.” 
145
   According to this typology, in 
respect of diabetes, conditions such as CVD, dyslipidaemia and hypertension would represent 
concordant co-morbidities.  
Of the co-morbidities noted in the present study, the overwhelming majority were concordant 
conditions: 92% were hypertensive while 10% had been diagnosed with CVD (19 had CCF and 1 had IHD) 
and 1 person had documented dyslipidaemia;  less than 9% had discordant disease.  The high prevalence 
of hypertension  reflects the observation that not only is this condition one of the two commonest co-
morbidities in diabetes
11
, but is also thought to occur in more than two-thirds of diabetic patients.
121
   
Other  South African studies that   looked at co-morbidity  mainly focused  on   hypertension
15,16,17
  and ,  
compared to findings in these,  the proportion of hypertension is significantly higher  in the present 
study:  Rotchford and Rotchford,  noted  hypertension  in 65.4% of the subjects studied
16
;  in the Motala 
study
17
, 68% of type 2 diabetics in their sample were hypertensive.  
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 While the overall prevalence of hypertension  is consistent across both  these studies, the results must 
be interpreted with some caution: one  difficulty in the Rotchford study
16
  is that the sample comprised 
a mixture of both   Type 1 and Type 2 diabetics,  although the former made up only 7.% of the sample;  
in the Motala study
17
, borderline hypertension was defined as a blood pressure of  greater than 140/90 
which seems to imply that patients with blood pressure equal to 140/90  were not  classified as 
hypertensive.  
In the present study, a greater proportion of glycaemic control is apparent in  individuals  with co-
morbid conditions than in those without.  However, although glycaemic control appeared to be better 
amongst the former, the actual proportion of  glycaemic control in this group was 25% which is 
significantly lower than that reported in other studies.
146,147
    Also, in the present study, the association 
between any co-morbidity and glycaemic control did not reach statistical significance.  The only 
exception was CCF: the presence of this concordant condition tripled the odds for controlled glycaemia.  
Other studies that looked at co-morbidities in terms of the Piette and Kerr typology demonstrate 
differing influence on gylcaemic control.  Alshamsan et al., found that mean HbA1c was lower in a 
cohort with concordant co-morbid conditions than in those with discordant or no co-morbid 
conditions
148
, while  LeChauncy et al., showed that the presence of any co-morbidity, concordant or 
discordant,  had twice the odds for better control than the absence co-morbidity.
149
  A more recent 
study by Pentakota et al., showed a still different pattern:  after controlling for a number of co-variates, 
those with either a discordant or a combination of a discordant and concordant condition, had lower 
odds for glycaemic control compared with those without any co-morbidity; the presence of a 
concordant condition did not confer better odds of control compared to not having any co-morbidity.
150
 
What these results  suggest is that analyses of glycaemic control using broad categorizations of co-
morbidity appear to be less informative than focusing on specific conditions, an observation 
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demonstrated in the present study and at least one other study elsewhere.
151
   Despite the lack of a 
clear pattern, the overall impression is that concordant co-morbidities appear to improve glycaemic 
control or, at worst, not degrade it.  
 One likely explanation for this is the relationship between the primary condition and concordant co-
morbidities: since these share similar pathophysiological characteristics and treatment goals, the 
implication is that treating one leads to commensurate benefits on the other which in turn might lead 
clinicians to more easily prioritize the management of this category of co-mobidity.
143
  On the other 
hand, discordant conditions represent diagnoses not related to the primary condition, often require 
more medications, and increase management demands on the clinician
145
; additionally, conditions such 
as depression have adverse effects on self-care behaviours such as medication adherence.
151
  The role of 
patient perceptions regarding the presence of co-morbid conditions as a motivating factor in better self- 
management is less clear.  A survey by Laiteerapong et al., suggests that the influence of such 
perceptions is a complex one since patients not only vary in their health priorities, but often disagree 
with health care providers on issues such as the importance of various co-morbidities and treatment 
preferences.
143
 
 
5.7.5  Race  
In the present study, the unadjusted odds for controlled glycaemia in individuals who were not Black 
was over three-fold of that for Black subjects.  Sub-optimal control amongst Black individuals has been 
demonstrated in various studies elsewhere.   Egede et al., who analysed variations in glycaemic control 
in a national sample of veterens in the U.S.A., found that odds for poor glycaemic control (which they 
defined as HbA1c > 8%), was 1.33 for  Blacks as compared to that for Whites.
152
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 In a study that assessed trends of HbA1c levels amongst diabetics in the USA between 1999 and 2004, 
data for the period 2003-2004 showed that 44% of African Americans had an HbA1c < 7% compared to 
64% of Whites.
153
   
Similarly, in the small South African study by Westaway et al., that looked at, inter alia, racial distinctions 
in glycaemic control, 12% of Blacks and 21% of Whites respectively, were noted to have good glycaemic 
control.
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In the present study, whether this racial association with glycaemic control reflects a relative disparity in 
socio-economic status, access to care or some other factor or factors, is not immediately evident since 
only a limited number of co-variates were tested. The only other demographic factor that was significant 
in the unadjusted model was residence, but this was on account of collinearity with race.   A number of 
explanations have been advanced by other researchers, and while there appears to be no clear 
consensus at this time, race specific HbA1c disparities   appear not to be influenced by processes
154
 or 
quality of care.
155
   Other clinical factors such as medication adherence and co-morbidity also seem to 
play no role.
152
   The influence of medication is unclear:  a 1994 study by Eberhardt   showed that insulin 
use, while not eliminating, did  diminish the association between race and HbA1c
156 
;  the more recent 
study by Egede et.al.,  demonstrated persistence of Black- White HbA1c disparity even after controlling 
for treatment type.
152
  Clinical inertia has been implicated in a 2011 study by Traylor et al., who 
demonstrated that African-Americans were less likely to receive treatment intensification compared to 
Whites.
157
  This might be relevant in the present study where the mean duration of insulin therapy in 
other race groups was double that in Blacks.( Appendix G, table G.2). 
  Another idea, postulated by Adams et al in 2008, suggests that Blacks might have more severe disease 
at diagnosis.
155
   This hypothesis has gained merit following subsequent work by Ziemer et al. in 2010.
158
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In this large cross sectional study, based on data from 2 other surveys in the USA, the investigators 
demonstrated that mean HbA1c levels were higher in Blacks as compared to that in Whites in non-
diabetic, pre-diabetic and diabetic subjects ; also, the differences were independent of glycaemic levels 
and were more pronounced in pre-diabetics and most pronounced amongst diabetics.  
 An additional, important finding was that, since the diabetic cohort in their study was newly diagnosed 
and not on any treatment at the time of the study, treatment modality was excluded as a possible 
factor. 
 
5.8 Implications of key findings in this study 
Key findings pertaining to the aim and objectives of this study are the low level of glycaemic control and 
the almost non-existent attention to some important processes of care.  These findings have significant 
and far reaching implications, on various levels, for the study population.  
Individuals with type 2 diabetes mellitus are at increased risk of neurological, cardiovascular and renal 
complications and these in turn have devastating effects on individual morbidity.  According to recent 
data released by the ADA, diabetes in adults confers a greater than 2-fold increased risk of 
cardiovascular disease, is the leading cause of blindness and kidney failure, and accounts for more than 
60% of non-traumatic lower limb amputations.
159
  Since, as demonstrated  in the literature review , 
complications in type 2 DM are strongly correlated with poor glycaemic control, the clinical  implications  
for the target  population of  the present study  are serious:  more than three-quarters are at  significant 
risk  of developing  one or more of the potentially life-threatening complications noted above.  This in 
turn translates to added socio-economic burden by way of increased health care costs, loss of income, 
productivity and stunted economic development through premature morbidity and mortality in the 
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economically active population.
1
   Increase in health care costs for diabetes is a particularly important 
challenge.  Estimates in the USA by the ADA, suggest that the cost of health care is more than 2-fold 
higher in patients with diabetes than in those without.
159
   According to projections by the IDF
160
, the 
prevalence of diabetes in Africa is expected to double by 2030, while expenditure on diabetes related 
health care is only expected to increase by 61%, a significant shortfall that is further likely to erode 
efforts aimed at controlling the disease. 
In view of this, the WHO, in concert with the World Bank, has proposed 3 interventions that are cost-
effective, life saving and feasible in resource constrained settings
161
: 
• Moderate blood glucose control with oral medication and, where needed, insulin. 
• Blood pressure control 
• Foot care 
The first of these has particular relevance to the present study where pharmacological treatment 
emerged as the only modifiable co-variate of glycaemic control. While clear guidelines exist for the 
initiation and intensification of glucose lowering agents, the extent of clinician adherence to these is 
unclear and requires elucidation through further research. In this regard, the question of possible delay 
in augmentation of oral medications with insulin is important. One South African study, conducted in 
primary care clinics in Cape Town, demonstrated a number of patient, service and clinician related 
barriers to insulin initiation.
162
   Similar research aimed at identifying and addressing barriers in the 
context of the present study has the potential for significantly improving glycaemic control. 
Processes of care, while not shown to influence glycaemic control, both in the present study as well as in 
other literature, is nevertheless an important component of diabetes care.  Process parameters 
measured in this study, as well as others such as regular, cholesterol measurements, urine screening for 
albuminuria, foot examinations and fundoscopy are vital in the monitoring of control and the 
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identification of complications.  Inadequate adherence to process of care issues pose a number of 
challenges to the patient, the clinician and the health care system. First, there is failure to identify and 
prevent the onset of the many life threatening complications of diabetes. Second, improvements in 
adherence to guidelines by clinicians will require a multi-faceted program   comprising a baseline audit, 
training in, and implementation of, current guidelines for processes of care and, regular post-
implementation audits   and feedback to clinicians for monitoring performance. That such an approach 
is effective in realizing the desired outcome of improved adherence to process of care standards, has 
been demonstrated in studies both locally and elsewhere.
13,120
   What is not clear, is whether this 
approach is feasible in the current context and this requires further study.  Finally, the implementation 
of adequate process of care practice has an attendant implication on health system resources by way of 
added costs of laboratory investigations and referrals.  However, simple processes such as BMI and WC 
monitoring, while realizing potentially enormous benefits accruing from monitoring overweight related 
cardio-metabolic risk, require no special skills or equipment. Furthermore, not all process need to be 
implemented at once: in addition to the processes of care measured in the present study, a reasonable 
point of departure would be the implementation of the following cost-saving WHO  recommendations
161
 
: 
• Screening and treatment of retinopathy to prevent blindness  
• Screening for early signs of diabetic-related kidney disease. 
Given the limited access to specialist ophthalmic services, the first of these is probably not immediately 
feasible in the context of the present study. However, recruitment of optometrists into the district 
health services could be a reasonable alternative for the establishment of an adequate retinopathy 
screening program. The second, while both feasible and easily implemented is often precluded on 
account of the lack of bed-side tests for albuminuria. 
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According to data released recently by Statistics South Africa  on causes of death in this country for 
2010,  not only was diabetes responsible for more deaths than HIV,  but, compared to 2009, there  was  
a 3.8%  increase in  deaths due to diabetes; the corresponding increase for HIV-related deaths was 
3%.
163
  Of particular note are the figures for Sedibeng District, where the present study was conducted: 
here, compared to the national figure of 3.9% of deaths attributable to diabetes, the disease accounted 
for 4.1% of all identified causes of mortality.
163
  These facts have two vital implications. First, a 
significant proportion of morbidity and mortality can be reduced by improving diabetic care and second, 
given the successes of the national HIV program, that a national, comprehensive plan, akin to that for 
HIV, is required to address the burgeoning diabetic epidemic and its attendant consequences. In this 
regard, IDF recommends an integrated approach involving three levels
160
: 
• Macro-level: development of policy and financing frameworks 
• Meso-level:  communities and health institutions where diabetic care is delivered 
• Micro-level: the individuals with diabetes, their families and immediate care-givers 
 
5.9 Limitations and strengths of this study 
Processes of care, delivery of lifestyle advice and pharmacological treatment represent a cluster of 
factors that describe what clinicians do as part of an overall management plan to  achieve specific 
quality and metabolic outcomes individuals with type 2 diabetes mellitus.  While there exists a 
plethora of research elsewhere that studied either of these factors, there appeared to be none 
locally, at the time of the current study, that comprehensively investigated all three.  This 
shortcoming is likewise reflected in studies that assessed the impact of these factors on glycaemic 
control.  Such studies were further compromised by a lack of consistent definitions of important 
parameters such as glycaemic and blood pressure control.   
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One  strength of the present study is the attempt to address these critical gaps in the corpus of local 
research.  In addition, this study looked at actual clinical practice and outcomes and thereby sought 
to provide insights into the management of type 2 diabetic patients within the constraints and 
challenges of a real world primary health care setting.  Additionally, analyses in this study were not 
limited to descriptive statistics; inferential and regression techniques were employed to uncover 
associations and control for potential confounders. 
This study has a number of limitations.  Potential  sources of bias have been previously noted and 
some of these need to be emphasized in so far as they potentially skew the outcomes reported in 
this study: first, since participation was entirely voluntary, selection bias is unavoidable and 
characteristics of non-participants  could not be checked for similarity to the final sample; second, 
absence  of documentation  of any  process of care in patient charts was deemed to indicate non-
performance  and this might have  under-estimated  the  proportions of achievement in this regard, 
and, finally recall bias as well as the Hawthorne phenomenon limits the validity of information on 
reported receipt of lifestyle advice by study participants . While every reasonable effort was made 
to locate research of relevance to the present study, the dearth of published South African studies in 
this regard restricted meaningful comparisons; logistic constraints precluded the possibility of 
accessing un-published work. 
 The observational design of this study is an important limitation.   Results of cross-sectional 
analyses, while revealing of associations between exposure and outcome variables, cannot be used 
to infer causality. Furthermore, limitations on the number of explanatory factors that can be tested 
within a given sample size leave open the possibility of unmeasured confounding variables in the 
absence of a control sample. 
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Finally, findings in this study have limited potential for extrapolation to other facilities within the 
district.  While catchment populations served by the various facilities might be similar, inter-facility 
variations with respect to clinical staff complements, protocols, practice and other factors such as 
access to laboratory tests, cannot be excluded. 
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CHAPTER 6 
CONCLUSIONS AND RECOMMENDATIONS 
_____________________________________________________________________________________ 
6.1 Conclusions 
The typical individual in this study was between 55 and 60 years of age, had some form of secondary 
education and was either employed or in receipt of a state pension.  The majority of the sample was 
diagnosed less than 20 years ago and had anthropometric profiles that conferred high cardio-metabolic 
risk.  More than 90% of the sample had at least one co-morbid medical condition and of these, 
hypertension was the commonest. 
High proportions of reported receipt of lifestyle advice in the past 12 months from a health care worker 
on weight control, diet or exercise were noted, with the majority reporting advice on all three topics.  
With the exception of blood pressure monitoring, significant shortcomings in clinicians’ adherence to 
SEMDSA guidelines for process of care measures in respect of HbA1c, weight, BMI and waist 
circumference monitoring in the preceding 12 months were demonstrated.  Oral hypoglycaemic drugs, 
either alone or in combination, were the most commonly prescribed drug type.  Insulin was most often 
combined with metformin, a prescription pattern in keeping with local guidelines for treatment 
intensification with adjunctive insulin therapy.   Only a minority of individuals was on insulin mono-
therapy. 
The majority of the sample  were found to have sub-optimal glycaemic control and, in the final adjusted 
logistic model, hypoglycaemic drug class emerged as the only modifiable parameter associated 
glycaemic control among the preset explanatory variables.    
 92 
 
The presence of CCF as a co-morbidity was associated with a higher proportion of glycaemic control 
compared to those without the condition and there was an inverse association demonstrated between 
glycaemic control and therapeutic combinations involving insulin.  In particular, combination therapy 
comprising either insulin and metformin or insulin, metformin and a sulphonyluria, conferred 
significantly worse levels of glycaemic control compared to that achieved using insulin alone.     
A critical gap in the management of adult diabetics identified in this study is the sub-optimal adherence 
to accepted standards for key process of care measures. While improvements in process of care 
measures do not necessarily lead to commensurate improvements in glycaemic control, the importance 
of such measures inheres in their ability to detect and improve quality of care and cardio-metabolic risk. 
 
6.2 Recommendations 
A number of gaps in the quality of care provided to adult diabetics were identified in this study.  Critical 
amongst these, and one requiring immediate attention, is the low level of adherence by clinicians to 
accepted standards for key processes of care.  The following are some recommendations to address this 
challenge:  
• Implementation of a continuous education program aimed at familiarizing clinicians with the 
contents and importance of process of care measures in the holistic management of adult 
diabetics.  It is vital that such a program be continuous since initial gains eventually fade as 
enthusiasm wanes. 
• Adoption of a standard set of guidelines, such as those recommended by SEMDSA, and the 
provision of practice aids in the form of charts and protocols. 
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• Provision of a reminder system, either paper- or computer-based, for anthropometric 
monitoring, laboratory investigations and referrals. 
• Regular practice audits to monitor and improve these strategies for enhancing process of care 
measures 
The District Family Medicine Unit is responsible for the implementation and monitoring of clinical 
quality in primary care facilities within Sedibeng District and, as such, responsibility for the 
implementation of these recommendations falls within its ambit.  As an initial step, the development 
and dissemination of process of care guidelines can be accomplished through the existing program of 
continuous medical education for district medical officers.  Subsequent implementation and monitoring 
should be conducted by sub-district family physicians through a combination of record reviews, audits 
and observed consultations.   
While a computer based reminder system might not be possible in the short term, the provision of a 
paper based system using pro-forma sheets in patient records detailing the various process of care 
schedules and reminders for clinicians, is both feasible and practical for immediate implementation   
 In addition, further research is required to elucidate two other issues arising from this study: 
• Despite high levels of reported receipt of lifestyle advice, the anthropomorphic profiles of 
patients in this study was unsatisfactory.  Since not all forms of lifestyle advice are efficacious, 
information regarding the type, quality and content of such advice currently being received is 
required to identify and address possible shortcomings in this regard. 
• A number of hypotheses have been postulated to explain the inverse association between 
glycaemic control and drug combinations comprising insulin and oral hypoglycaemics found in 
this study.  Additional investigations are required to test these and other possible explanations 
for this anomalous finding. The identification  and management of barriers in this regard has the 
 94 
 
potential benefit of significantly improving overall rates of glycaemic control in the study 
population  given that one-third of the sample is on combined insulin and oral treatment. 
In addition to a general program of continuing medical education, the District Family Medicine Unit 
maintains an academic program for family medicine registrars. As part of their academic training , 
registrars are required to conduct  clinical audits , quality improvement projects as well as research 
projects in district facilities. In this regard, the unit is ideally placed to address these research questions 
within its existing academic program without the necessary deployment of additional resources. This is 
both practical as well as cost-effective, particularly in resource-constrained settings such as that where 
the current study was conducted.  Research  recommendations  will be communicated to the HOD of the  
Family Medicine Department at WITS Medical School for consideration as topics of research for future 
family medicine registrars.  
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APPENDIX A 
INTERVIEW QUESTIONNAIRE 
SOCIO-DEMOGRAPHIC DATA AND DIABETIC SELF-CARE INFORMATION 
 
Section A. Socio-demographics 
 
Reference: ________________________                             Date:________________ 
Date of birth:_____________________              Sex:  M /  F 
Place of residence: _______________________   
Highest level of schooling: primary/secondary/other__________________            
Employment status:  Employed/unemployed/self-employed 
 
Section B. Self-care information 
1. When were you diagnosed with diabetes? 
2. Over the last 12 months, has any health worker at the clinic advised you about the following 
issues regarding diabetes: 
• Exercising regularly             Y/N 
• Following a healthy diet       Y/N 
• Controlling your weight        Y/N 
 
4.        Anthropomorphic measurements 
 Height__________    Weight__________   Waist Circumference________ 
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APPENDIX B 
CLINICAL RECORD AND PROCESS OF CARE DATA EXTRACTION SHEET 
1. Co-morbid conditions: 1)_______________2)_____________3)______________4)_____________ 
2. Medications and doses: 
a. Glibenclamide 
b. Glicazide 
c. Metformin 
3. Insulin (Y/N)   Duration ( Months)_________ Type ( Basal/Biphasic/ Basal-Bolus) 
4. Process of care performance over the preceding 12 months 
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5.  HbA1c requested  Y/N      Result________%  
 
 
 
 
 
 
 
 
 
 
 
 
 
Month 1 2 3 4 5 6 7 8 9 10 11 12 
Visit Y/N             
Blood glucose               
HbA1c             
WC             
Body weight kg             
BMI             
BP             
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APPENDIX C 
WITS HREC CLEARANCE CERTIFICATE 
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APPENDIX D 
SEDIBENG DISTRICT HEALTH SERVICES PERMISSION TO CONDUCT RESEARCH 
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APPENDIX E 
PATIENT INFORMATION SHEET 
 
THE ROLE OF PATIENT FACTORS AND PROCESSES OF CARE IN THE GLYCAEMIC CONTROL OF TYPE II 
DIABETES AMONGST ADULTS ATTENDING THE JOHAN HEYNS COMMUNITY HEALTH CENTRE. 
 
Dear Sir/Madam, 
 
My name is Dr Kalain and I am a post-graduate student in Family Medicine at WITS University. As part of 
my studies, I am doing a research project on diabetes at Johan Heyns Clinic. I want to find out how well 
diabetes is controlled in patients attending this clinic and also to understand some of the reasons for 
satisfactory or unsatisfactory control. 
 To obtain the necessary information to answer these questions, I request your voluntary participation  
to do the following: 
• Conduct a short interview  where I will ask questions about diet, weight and exercise.  
• Look at your clinic file to see whether things like blood sugar, weight ,height  and waist are 
checked and also to find out what medications are being taken for diabetes and other problems 
• If necessary, I will have your  height ,weight and waist measured and also request a blood test 
for sugar to be done. 
The interview should take no longer than 10 minutes and your usual consultation for which you are 
attending will not be affected. There are no risks or benefits to you from participating in the study. 
I want to re-assure you that: 
• Participation is completely voluntary and that it is your right to withdraw at any point during the 
process without giving a reason. Non-participation or withdrawal carries no penalty whatsoever 
and will in now way adversely affect your medical care at the clinic  
• No sensitive information will be required and any information obtained will be treated with the 
strictest confidentiality. Your name will not be recorded during the process.  
• The information required for this study is no different from that required by your doctor or 
nurse during your usual consultations at the clinic for diabetes. This is also true for the height, 
weight and waist measurement as well as the blood sugar test. 
 
Should you volunteer to participate in the study, you will be requested  to give written consent after 
reading and signing the attached consent form. 
Should you have any queries or concerns, please feel free to contact me, Dr A Kalain, at the following 
telephone numbers: 
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• 016 950 6000 – Johan Heyns Community Health Centre. 
• 016 950 6267- Sedibeng District Health Office. 
• 083 468 6922 – 24 Hours 
Thank you 
 Dr A Kalain. 
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APPENDIX F 
INFORMED CONSENT FORM 
INFORMED CONSENT: 
• I hereby confirm that I have been informed by the study doctor, Dr A Kalain, about the nature, 
conduct, benefits and risks of clinical study : “ The role of Patient  Factors and Processes of Care 
in Glycaemic control amongst patients with Type 2 Diabetes attending the Johan Heyns 
community health centre in Sedibeng District.” 
• I have also received, read and understood the above written information (Participant 
Information Leaflet and Informed Consent) regarding the  study. 
• I am aware that the results of the study, including personal details regarding my sex, age, date 
of birth, initials and diagnosis will be anonymously processed into a study report. 
• In view of the requirements of research, I agree that the data collected during this study can be 
processed in a computerised system by the study doctor.  
 
• I may, at any stage, without prejudice, withdraw my consent and participation in the study. 
 
• I have had sufficient opportunity to ask questions and (of my own free will) declare myself 
prepared to participate in the study.  
 
PARTICIPANT: 
 
 
Printed Name     Signature / Mark or Thumbprint   Date and Time 
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I, Dr A Kalain herewith confirm that the above participant has been fully informed about the nature, 
conduct and risks of the above study. 
 
 
 
STUDY DOCTOR: 
 
Printed Name   Signature                  Date  and Time 
 
 
 
 
TRANSLATOR / OTHER PERSON EXPLAINING INFORMED CONSENT…………………(DESIGNATION): 
 
 
Printed Name    Signature    Date and Time 
 
 
 
WITNESS (If applicable): 
Printed Name    Signature             Date and Time 
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APPENDIX G 
ADDITIONAL RESULTS NOT SHOWN IN CHAPTER 4 
Table G.1 Duration of diabetes and insulin in individuals on oral and insulin therapy (n=62) 
 Minimum  Maximum  Median  
Diabetes duration ( years) 1 21 7 
Insulin duration ( months) 1 104 16 
 
Table G.2 Insulin duration by race  
 Blacks  Other races  p-value for difference in means  
Mean insulin duration ( months): 
 insulin and oral therapy or insulin only 
(n=70) 
26.2 51.33 0.0165 
Mean insulin duration ( months): 
 insulin and oral therapy  
(n=62) 
23.6 40.8 0.0864* 
*not statistically significant 
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APPENDIX H 
APPLICATION FOR CHANGE OF TITLE 
 
